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Introduction: Despite a lower incidence of breast cancer (BrCA) among Black women 
in the U.S. compared to White women, Black women experience consistently higher 
mortality rates. The aims of this study were 1) to assess the relationship between race and 
diagnosis-to-treatment times 2) to assess racial disparity in mortality among Black and 
White BrCA patients in SC and 3) assessment of the validity of the Mortality-to-
incidence ration (MIR) as a proxy for survival and geospatial investigation of racial 
disparity among breast cancer (BrCA) patients. 
Methods: Breast cancer cases diagnosed between 2002-2010 were obtained 
retrospectively from the SC Central Cancer Registry, linked with administrative data 
from a private payor source and Medicaid Plan. The main exposure variable for all 
analyses was patient’s race (White vs Black women). For aim 1, outcome variables were 
diagnosis-to-treatment time for BrCA-related surgery, radiation, adjuvant hormone 
treatment (AHT) and chemotherapy; Chi-square tests, logistic regression and generalized 
linear model analyses were conducted to compare patients’ diagnosis-to-treatment times 
among Blacks and Whites. For aim 2, the main outcome variable was mortality 
characterized by vital status and total survival time; Cox proportional hazard analyses 
were conducted to compare hazard ratios among Blacks and Whites to assess disparities 
in mortality. For aim 3, MIRs were computed from cancer incidence and mortality data 
which were obtained from the SC Community Access Network (SCAN). ArcGIS 10.2 
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was utilized to map BrCA MIRs by race (46 counties and 4 regions). MIR were 
categorized into seven levels using the national BrCA MIR for White women as 
reference in county maps; in all other maps, categorizations were based on natural breaks 
in ArcGIS. Survival percentage, Cox Proportional hazard ratios and survival-MIR 
correlation analyses were computed for all BrCA cases in each county/region utilizing 
SAS software and data on BrCA cases which were obtained retrospectively from the SC 
Central Cancer Registry from 2002 to 2010. 
Results: A total of 2155 BrCA patients with 1557 White women and 598 Black women 
were reported in the study period (2002-2010). For aim 1, multivariable linear model 
regression showed that there was statistically significant increase in adjusted least square 
means in receipt of AHT by 54 days, 36 days, 63 days and 46 days among unmarried, not 
being on best chance network and late surgery; multivariable logistic regression showed 
that the odds of late receipt of surgery was 1.96 (95% CI: 1.38-2.79) among unmarried 
Black women compared with unmarried White women; 1.89 (95% CI: 1.32-2.71) among 
Black  women who lived <=10 miles to their health providers compared to White women 
who lived <=10 miles; and 1.40 (95% CI: 1.08-1.82) among Black women who live in 
urban areas compared with White women who lived in urban areas. For aim 2, 
multivariable Cox proportional hazard that adjusted for cancer stage showed that the 
hazard ratio of mortality was 3.45 (1.64, 7.25) among Black women who lived in Low 
Country region of the state compared with White women who lived in Low Country 
region of the state. There were no statistically significant differences between White and 
Black women in the other 3 regions of the state (Midlands, PeeDee and Upstate). For aim 
3, there were multiple statistically significant correlations between MIR and survival 
vi 
 
overall; MIR and survival among Whites; and Black-White difference in MIR versus 
Black-White difference in survival (all p-values were <0.05). Low Country region was 
identified as the region with worse Black-White MIR and survival disparity. 
Conclusions: Mortality was higher among Blacks who lived in the Low Country region 
of the state and among Blacks who lived in urban areas. Health region ranking utilizing 
the MIR correlated with 12-year survival time in the overall population, Whites and 
Black-White difference. To improve overall timely receipt of AHT, efforts need to be 
directed at Black BrCA patients that are not married, not on BCN, and those that received 
late surgery. To improve overall timely receipt of surgery, efforts need to be directed at 
Black BrCA patients that are not married, lived in urban areas and lived <=10 miles from 
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Statement of the Problem 
 
Statistics over the past 20 years in the United States have shown higher mortality 
rates among Blacks with breast cancer (BrCa) compared to Whites despite lower 
incidence of BrCa among Blacks. (1-4) In South Carolina (SC), there is a 60% higher risk 
of Black women dying from BrCa compared to White women (5), with an even higher 
risk of BrCa mortality among those with a low socioeconomic status. (6, 7) A delay in the 
commencement of treatment has been hypothesized as one of the possible reasons for the 
higher mortality among Blacks despite lower incidence over the years. (3) Survival 
studies have shown that a treatment delay of as little as two months is associated with less 
favorable survival among BrCa cases. (3, 8, 9) 
The mortality-to-incidence ratio (MIR) is a unique way to quantify cancer 
disparities based on race (5, 10). The MIR is an important indicator that offers additional 
information beyond what is represented through the individual incidence and mortality 
rate measures (5), however, few studies have used MIRs to compare cancer rates (5, 11-
13). Wagner et al. described racial cancer disparities and their potential geographical 
determinants by calculating, comparing and mapping MIRs throughout the state of 




than Whites for all cancer sites evaluated (10). Furthermore, Sunkara et al. demonstrated 
a strong linear relationship between the MIR for colorectal cancer and health system 
rankings across the countries evaluated (14). While there are many advantages to using 
the MIR as surveillance tool, MIR lacks the ability to capture loss to follow up and 
censoring. However, survival analyses can capture and account for follow up. Due to this 
difference between MIR and survival analyses, there is need to conduct sensitivity 
analyses to compare rankings between MIRs and median survival times across regions in 
SC by race. This will serve to validate the MIR. 
Background 
 
The time from diagnosis to the first course of treatment among cancer patients, 
including BrCa patients, increased from 1995 to 2005. (15) From 1995 to 2005, there was 
an increase in average wait time to BrCa surgery from 21 days to 32 days, clearly 
revealing an increase of 11 days over the years. (16)  Diagnosis-to-surgery wait times 
among BrCa patients in the United States have also increased over the past 20 years. (15, 
17, 18) In terms of surgical interventions for BrCa patients, disparities exist between 
races in wait times from diagnosis to surgery, with significantly higher odds of delayed 
treatment among Blacks and Hispanics. (18)  
The various forms of delay that Black women diagnosed with BrCa experience 
are related to diagnosis, (19) as well as time to surgery, (3, 20, 21) chemotherapy, (4, 22, 
23) adjuvant hormonal therapy,(24-26) and all forms of treatment combined. (27, 28) 
Documented factors that affect delay in treatment among BrCa by race include age, (28) 




adjuvant therapy among BrCa patients have been shown to worsen survival (18, 29) and 
increase patient anxiety. (18) 
Previous studies have utilized the MIR as a surveillance tool and shown that SC 
exhibits more extreme racial differences in cancer incidence, mortality and MIR than 
other states or the nation. (30-38) Additionally, examining the MIR helped to highlight 
health regions where this disparity is highest. (38) The MIR also serves as a population-
based approximation of fatality (1/survival) given incidence by stabilizing the incidence 
and mortality differences across cancer sites and racial groups (5, 10). The MIR is also a 
unique way to quantify racial cancer disparities (5, 10). Few studies have used the MIR to 
compare cancer rates (5, 11-13). Wagner et al. described racial cancer disparities and 
their potential geographical determinants by calculating, comparing and mapping MIRs 
throughout the state of Georgia (GA, United States) and found that Blacks in GA had 
higher rates of fatal cancers than Whites for all cancer sites evaluated (10, 14). Strong 
recommendations have been made for cancer surveillance programs to use MIRs to 
monitor disparities across racial/ethnic groups and geographic regions (5, 10-14, 38) as a 
proxy for survival, but there has not yet been a study to assess the effectiveness of MIR 
as a proxy for survival among BrCa patients, especially in South Carolina where there is 
marked Black-White disparity. (38) 
Proposal and Specific Aims 
 
Effective reduction of disparities in treatment delays and mortality among racial 
minorities will require the identification of the mechanisms by which these disparities 




utilizing data derived from all female BrCa cases over eight years from the SC Central 
Cancer Registry linked with administrative medical and pharmacy claims data for the 
Public Employee Benefits Plan (private, state-subsidized insurance plan for state 
employees) and Medicaid.  
This combination of data from both publicly and privately insured BrCa patients 
will be utilized to assess the complex interplay between geographic factors and racial 
disparities using Geographical Information System (GIS) mapping, survival methods and 
multilevel models to identify predictors of treatment delays and mortality that can be 
intervened upon. GIS methods have been utilized to identify possible predictors of racial 
disparities in breast cancer survival. (39) However, GIS methodology has not been 
utilized to specifically identify individual- and area-level characteristics that may 
contribute to BrCa mortality among Blacks within the context of multilevel survival 
modeling. Recognition of the causes of disparities in small-area variation in BrCa 
survival has the potential to allow the application of evidence-based approaches to reduce 
disparities. (39)  
The aims of this study therefore are to 1) assess racial disparities in treatment 
delays and the utilization of adjuvant hormonal therapy (AHT) among patients diagnosed 
with breast cancer and 2) identify predictors of dissimilarity in breast cancer-related 
survival by health regions among Black women in SC utilizing multilevel survival 
models and GIS methodologies. The above-mentioned dataset will also be used for 
survival analyses to compute the median survival time for the four health regions in SC in 
order to rank the health regions. Thereafter, the survival and the ranking derived from the 




The Specific Aims 
 
1. To assess racial disparities in breast cancer treatment time in South Carolina (SC). 
a. To compare wait times from diagnosis to the various forms of treatment in 
Blacks and Whites with BrCa. 
b. To assess the effect modifiers (diagnosis year and rural/urban status) that 
affect the relationship between race (Black vs White) and diagnosis-to-
treatment wait times for the different treatment types. 
Hypothesis: We hypothesize that the diagnosis-to-treatment wait time is higher among 
Blacks compared to Whites for all BrCa treatment types in SC. We also hypothesize that 
diagnosis year and rural/urban status will be an effect modifier in the relationship 
between race and diagnosis-to-treatment wait times. Assessing for effect modifications 
between race and important modifiers will also help identify specific modifier groups that 
help explain the racial disparity among Blacks, which will aid in the development of 
multilevel interventions. 
2. To identify patient- and neighborhood-level predictors of dissimilarity in breast 
cancer-related survival among Blacks and Whites in SC utilizing multilevel (state and 
regional) survival models. 
a. To analyze the breast cancer-specific and overall survival in SC as a whole, as 
well as by four health regions, utilizing the Kaplan-Meier curve and median 
survival time. 
b. To identify predictors of survival by four health regions utilizing the Cox 




Hypothesis: We hypothesize that treatment and mortality outcomes will be worse in 
Regions 6 and 4, which are characterized by lower socioeconomic status, and will be 
better in Regions 2 and 7 because of the major hospital systems available in these 
regions. 
3. To compare MIR methodology with survival methodology in assessing racial BrCa 
disparities over the eight-year period across the four health regions in SC. 
a. Describe BrCa disparities in SC among Blacks and Whites using MIRs by 
race for the four health regions within SC.  
b. Rank the four health regions by race from the worst to the best using MIRs. 
c. Compute the median survival time by race in the four health regions. 
d. Rank the four health regions by race from the worst to the best using median 
survival times. 
e. Compare the rankings based on MIRs to those from median survival times to 
see where differences exist.   
Hypothesis: We hypothesize that the findings from MIR by regions will be similar to the 
survival analyses by regions.  
 
Significance of this study 
 
Although various studies in other states consistently show that Black women with 
BrCa experience delays in receipt of surgery, chemotherapy, AHT and radiation, (3, 4, 
19-23, 27, 28) this has not been examined in SC, which has a high representation of 




incidence and mortality (30-38). In addition, the possible factors that affect racial 
disparity in treatment delays in SC have not been examined. 
The need to study predictors of disparities in diagnosis-to-treatment times and 
their effects on survival among BrCa patients in SC is particularly important because 
Black-White disparity in BrCa mortality is of a higher magnitude in SC (30, 40, 41); 
mortality among White BrCa patients is 7% lower in SC compared to the national 
average and is 29% higher among Blacks in SC (30, 40, 41). Also, in SC, mortality from 
BrCa amongst Blacks is greater than 60% higher than that of Whites (5). Studies also 
show that Blacks experience worse mortality outcomes after matching for known 
prognostic factors, and this finding has persisted over time (42-45).   
A study that used three cutoff points (30, 60, 90 days) to define a diagnosis-to-
surgery delay showed that Black women were more likely to experience delays compared 
to White women, and this association was independent of health insurance status, age at 
diagnosis and cancer stage at diagnosis (46). There is therefore a need to assess other 
factors that influence delay to surgery apart from health insurance, age at diagnosis and 
cancer stage at diagnosis and to examine how these factors interplay with survival 
outcomes (21). This study was able to assess other factors such as marital status, county 
of residence (whether rural or urban), year of diagnosis, hormone receptor status, 
enrolment in BCN (dichotomized as yes or no), and tumor grade of BrCa at diagnosis. 
This study also helped to assess the extent to which radiation treatment guidelines 
are being adhered to among BrCa patients in SC. For example, the national guideline 




Oncology (ASCO) states that BrCa patients who have high risk for locoregional 
recurrence should receive postmastectomy radiation (PMRT) (47-52). This study helped 
to assess if PMRT is being adhered to and if racial disparities exists in SC. Additionally, 
the effect of diagnosis-to-radiation time and surgery-to-radiation time on survival by race 
in SC added to current body of knowledge (53) in overall survival and BrCa specific 
survival. This study also helped to assess the extent to which chemotherapy treatment 
guidelines are being adhered to among BrCa patients in SC. For example, the 
recommendation from clinical trials is that adjuvant chemotherapy be initiated within 3 
months after surgical intervention (54).  
Because of the excess contribution of hormone receptor negative (HRN) BrCa 
patients to mortality among BrCa patients, it is important to study and identify factors 
that are associated with the receipt of recommended treatment guidelines, inclusive of the 
recommended 60 days between diagnosis and treatment for BrCa among HRN BrCa 
patients (55). This information will help guide interventions that will help reduce 
disparities among Black women (55). 
The association between race and commencement of AHT is not well elucidated 
and appears to be incompletely studied and controversial; thus, further work is required. 
In North Carolina (NC), statistically significant racial disparity in commencement of 
AHT has been demonstrated: Blacks were less likely to commence AHT, and this racial 
disparity was more pronounced among the subpopulation of patients that did not receive 
chemotherapy. (26) However, in a previous study in SC, there was no racial difference 
found between Blacks and Whites in the commencement and early use of AHT, but 




associated with commencement/early use of AHT. (6) In SC, contrary to the finding in 
NC, overall use of AHT was worse among patients who received AHT and/or radiation. 
(6) In the study described above in NC, the BrCa cases were privately insured (26); 
however, in the study in SC (6), the BrCa cases were on Medicaid insurance. Perhaps the 
difference in the insurance payer of the BrCa cases between the two studies could help 
explain the differences in the results. To further understand the interplay between race, 
commencement of AHT and other forms of treatments for BrCa, there is a need to 
analyze data on all BrCa cases derived from the Central Cancer Registry linked with 
administrative medical and pharmacy claims data for the Public Employee Benefits Plan 
(private insurance) and Medicaid. This study will be able to achieve this.  
This study also added to existing body of literature on racial disparities BrCa-
specific survival (BSS), (56) and overall survival (OS) (57, 58). Assessment of predictors 
of survival differences in this study by regions in SC has not been studied before 
therefore findings from this research will help navigation programs to identify regions 
with higher racial disparities and also help to identify possible modifiable predictors that 
are driving the disparities. 
The epidemiologic use of the MIR in cancer research is gaining significance and 
is increasingly used. (5, 10-14, 38) A major drawback of the MIR, however, is that there 
is no method to account for censoring and loss to follow up. Additionally, the MIR most 
likely counts the mortality from previous years while using incidence from the current 
year hence it is not a classic case fatality proportion.  It is also not possible to adjust for 
covariates such as treatment, comorbidities or individual socioeconomic status in MIR 




the denominator (incidence) may not be direct because persons diagnosed with BrCa may 
not die of BrCa, and persons who die after the diagnosis of BrCa will survive for varying 
lengths of time, which the MIR cannot account for. 
The limitations of the MIR described above make it difficult to compare results of 
MIR studies directly with those of survival studies. Survival studies are more complex, 
time-consuming and expensive and require more skills to carry out. Using MIR is less 
time-consuming, less expensive and requires fewer skills to carry out. (5) The potential 
utility of the MIR in cancer surveillance programs for monitoring disparities across 
racial/ethnic groups and geographic regions is substantial, as shown by previous studies. 
(5, 10, 12, 14, 38) It is therefore important to see how the MIR compares with survival 
studies in identifying racial disparities and in ranking health regions for the purpose of 
surveillance.  
This study found that the health region rankings are similar whether using MIR or 
survival time, hence it may be preferable to use the cheaper, faster and less time-
consuming MIR, which also requires fewer skills, to identify racial disparities and rank 
health regions to identify areas that require urgent attention/interventions. To our 
knowledge, this is the first study that sought to directly compute MIR by health regions 
and compare this ranking with a ranking produced by median survival time to further 
substantiate the usefulness of the MIR in resource-poor settings and in quick decision 
making to identify areas that need urgent interventions. 
Additionally, a previous report shows that predictors that are environmental in 




been well explored among younger women. This is particularly important because young 
Black women (less than 65 years old) present with relatively more fatal BrCa, leading to 
higher mortality among this group. (30, 40) This proposed project aims to focus on this 
relationship among the target population. 
Overall, the study population (SC) being considered in this study is unique 
because of the high proportion of SC residents that live in rural areas and the high racial 
disparity found in SC in other studies. The proposed analytic techniques in this study are 
also unique because the MIR has not been utilized to assess BrCa disparities in SC and 
this will be the first study conducting a direct sensitivity analyses comparing MIR with 
survival analyses both on the state-wide level and regional level. Identifying predictors of 
racial differences in survival by regions is also unique as findings has the potential to 
















Disproportionate Breast Cancer Burden among Blacks  
 
Despite the awareness and funding dedicated to closing the racial gap in cancer 
therapy, it is discouraging to note that racial disparities persist in BrCa mortality (60, 61). 
Compared with non-Hispanic Whites, Blacks bear an excessive public health burden of 
BrCa in the United States (1, 2, 62). Mortality due to BrCa is encountered at a much 
higher rate among Blacks compared to Whites (40, 63, 64). Mortality from BrCa is about 
40% higher among Blacks compared to Whites, although Whites have a higher likelihood 
of being diagnosed with BrCa (6, 65, 66). The lifetime probability of developing BrCa is 
1 in 9 among non-Hispanic Whites and 1 in 8 among Blacks. However, the lifetime 
probability of dying from BrCa is 1 in 37 among non-Hispanic Whites but 1 in 31 among 
Blacks (2). The mortality rate from BrCa is 22 per 100,000 among non-Hispanic Whites 
and 31 per 100,000 among Blacks (2).  
Although the Black-White disparity in BrCa mortality is seen both at the national 
level and in SC specifically, the disparity is of a higher magnitude in SC (30, 40, 41); 
mortality among White BrCa patients is 7% lower in SC compared to the national 
average and is 29% higher among Blacks in SC (30, 40, 41). Also, in SC, mortality from 




show that Blacks experience worse mortality outcomes after matching for known 
prognostic factors, and this finding has persisted over time (42-45).   
Results from meta-analyses of BrCa that were conducted in 2002 and 2006 
showed that there was about 20% excess risk of death among Blacks compared to Whites 
(67, 68). The pooled hazard ratio of mortality among Blacks compared with Whites was 
1.22 (95% C.I.: 1.13-1.30) in 2002 and 1.28 (95% C.I.: 1.18-1.38) in 2006 (67, 68). The 
meta-analysis revealed that there were clear survival disadvantages among Blacks with 
BrCa in all studies considered (67, 68). 
Factors that Contribute to Higher Mortality among Black BrCa Cases Compared to 
Whites 
 
Identified factors that contribute to a higher mortality among Blacks compared to 
Whites in the US are socioeconomic status, tumor biology (more aggressive tumors), 
disability, environmental factors, comorbidities, cultural differences, late stage at 
diagnosis and age at diagnosis (21, 22, 41, 69-77). Severe obesity and high waist-to-hip 
ratio among Blacks have also been found to contribute to racial differences in stage at 
BrCa diagnosis, as Blacks had a higher likelihood of severe obesity and being in the 
highest tertile of waist-to-hip ratio (64).   
Blacks also have various barriers to accessing care and have been shown to 
consistently receive lower-than-recommended BrCa care when compared with their 
White counterparts (21, 25, 43, 61, 73, 78). This includes lower-than-recommended rates 




shown to be 30-40% more likely to receive BrCa treatments that are not in line with 
guidelines across all BrCa subtypes (79). 
Socioeconomic status (SES) has been identified as one of the main drivers of 
racial disparities in BrCa mortality, as women in low socioeconomic levels tend to 
present with more advanced-stage BrCa, which usually has poorer prognosis (71, 80). 
Generally, the five-year survival rate is worse among population subgroups with lower 
SES, which are usually comprised of a large proportion of Blacks (71, 81). Whereas 
about 12% of Whites live below the poverty level, this proportion is 26% among Blacks 
(71, 82).  
Previous studies have also shown that there is a tendency among Blacks to not 
receive preventative services such as early screening mammograms (77). Blacks are also 
likely to have BrCa with low pathologic complete response (pCR) to chemotherapy (56). 
pCR has been shown to be a major prognostic index, as higher pCR has been linked with 
better survival outcomes (56). Blacks have also been shown to have a larger median 
tumor diameter at presentation and also to present with triple-negative BrCa (TNBC) 
(83). 
Treatment Guidelines for Breast Cancer 
 
The national guideline consensus by the National Institutes of Health (NIH) and 
American Society of Clinical Oncology (ASCO) states that BrCa patients who have high 
risk for loco-regional recurrence should receive post-mastectomy radiation (PMRT) (47-
52). For stages I and II BrCa, there are two recommended forms of treatment: 




therapy; and a modified form of a radical mastectomy with or without radiation therapy 
(78, 84, 85). PMRT is indicated only when the tumor size is large and three or more 
lymph nodes are affected (43, 84-86). A study that assessed the recurrence of BrCa 
comparing women with lumpectomy without radiation therapy and women with 
lumpectomy with radiation therapy showed recurrence rates of 14% and 39%, 
respectively, among the two groups (53). 
Both forms of treatments for stage I and II BrCa have been shown to lead to 
similar outcomes (53) in overall survival, disease-free survival and distant disease-free 
survival. An additional recommendation for women with hormone receptor–positive 
(HRP) BrCa is that those women with progesterone-positive (PR) or estrogen-positive 
(ER) BrCa receive AHT for five years post diagnosis. (43, 85). This recommendation is 
particularly useful for all BrCa that is 1 cm or greater in size. Irrespective of the stage or 
size of the BrCa, the guideline recommends that ER or PR status should be determined 
(43, 85). 
A predefined cutoff of 60 days was set by the National Breast Cervical Cancer 
Early Detection Program (NBCCEDP) between an abnormal screening test and diagnosis 
and between diagnosis and initiation of treatment (21, 60, 74). The cutoff set by 
NBCCEDP is that BrCa patients who experience delays of more than 60 days in initiation 
of treatment should not comprise more than 20% of all BrCa patients (21, 60, 74). The 
NBCCEDP has seen some success in the initiation of treatment for BrCa as a result of 





Definition and Importance of Treatment Delays among BrCa Patients 
 
The treatment interval was defined as the time in days between diagnosis of BrCa 
and initiation of treatment, as in Caplan et al., Connors et al. and McLaughlin (8, 74, 88). 
The date of diagnosis was defined as biopsy date, which was utilized as a proxy for 
biopsy-confirmed BrCa diagnosis (8, 74, 88). The date of initiation of treatment was 
defined as the date of definitive surgery, the date of initiation of neoadjuvant 
chemotherapy or the date of initiation of AHT (8, 74, 88). For surgical treatment, 
definitive surgery was determined as the most invasive surgery of the primary BrCa site 
(74, 89). Examples of definitive surgeries include mastectomy, lumpectomy, excisional 
biopsies and re-excision of the site of biopsy (74, 89). 
Other authors have referred to the treatment interval by other names, such as 
treatment delay or delay interval (90, 91). Past categorizations of treatment intervals have 
used 4 groups, i.e., <30, 31-59, 60-69 and >90 days (74, 89). Another author used the 
term time to primary treatment (TPT) to describe period between the date of pathological 
diagnosis and the date of primary treatment (92). BrCa patients have also been defined as 
having a treatment delay if they had a treatment interval greater than 60 days (74, 89).  
As mentioned above, those patients who experience delays greater than 60 days should 
not comprise more than 20% of the total patients, according to NBCCEDP (21, 60, 74). 
However, studies show that delays greater than 90 days have the potential to lead to 
worse BrCa outcomes, especially poorer survival (8, 54, 74, 93). 
The diagnosis-to-treatment interval is an important quality measure that is 




American Society of Breast Surgeons (ASBS) and the National Quality Measures for 
Breast Care (NQMBC) (94-96). The NAPBC, ASBC and NQMBC all serve to validate 
breast cancer care rendered by hospitals (94-96). However, there has been no formal 
agreement on what constitutes an acceptable delay in terms of quality of BrCa care 
measures (94-96). Another reason that the diagnosis-to-treatment wait time is important 
is that studies have shown one of the most overwhelming, distressing and anxiety-
producing periods for BrCa patients is the waiting time between an abnormal 
mammogram and treatment initiation (94, 97). 
Racial Disparities in the Receipt/Delay in the Receipt of Recommended Treatments 
 
Generally, disparity in the utilization of various treatment forms such as surgery, 
radiotherapy, chemotherapy and AHT has been hypothesized as the cause of the 
disproportionate increase in mortality from BrCa (21, 77, 98). There is a higher 
likelihood that a Black woman will experience treatment delay and/or discontinuation of 
treatment for BrCa when compared with a White woman (46, 90, 99). Fedewa et al. 
found that irrespective of stage of BrCa at diagnosis, age and the health insurance status 
of the BrCa patient, Blacks had a higher likelihood of delay in receipt of treatment for 
BrCa (46). Another study also showed that the odds of a Black BrCa patient experiencing 
diagnosis-to-treatment delay beyond 1 month were 1.6 times (95% C.I.: 1.4-1.9) those of 
White women (90). 
A study in Missouri showed that the median diagnosis-to-treatment wait time for 
any first course of treatment among Blacks was 27 days and that about 12% of Black 




diagnosis-to-treatment wait time was 22 days (8). Similar results were also seen 
internationally, as a study in Malaysia found that the median TPT was 18 days, and most 
of the BrCa patients’ primary treatment was surgery (92). 
Surgery 
 
To define a delay, a predefined cutoff of 60 days was set by the NBCCEDP 
between abnormal screening test and diagnosis and also between diagnosis and initiation 
of treatment, which is surgery in most BrCa cases (21, 60). Compared with White 
women, a large proportion of Blacks do not undergo surgical intervention for invasive 
BrCa (72).  There has also been an increase over time in the diagnosis-to-surgery wait 
time among Medicare patients from 29 days (1992) to 32 days (2006) (16). In addition, 
another study showed that time to surgery increased over time from a mean of 22 days 
(1998) to 31 days (2003) to 41 days (2008) (100). A study assessing the effect of race on 
diagnosis-to-treatment time showed that about 15% of Blacks experienced treatment 
delay (>6 weeks) compared to about 8% of White women (9). Sheppard et al. showed 
that the mean diagnosis-to-treatment time for Blacks and Whites were 47 days and 33 
days, respectively, and that Black women were 58% less likely to have surgery within 90 
days (21).  
A study that used three cutoff points (30, 60, 90 days) to define a diagnosis-to-
surgery delay showed that Black women were more likely to experience delays compared 
to White women, and this association was independent of health insurance status, age at 
diagnosis and cancer stage at diagnosis (46). Another study that utilized a cutoff point of 




5.0) compared to White women (98). There is therefore a need to assess other factors that 
influence delay to surgery apart from health insurance, age at diagnosis and cancer stage 
at diagnosis and to examine how these factors interplay with survival outcomes (21). 
Some of the factors that were identified as delaying the interval from diagnosis to surgery 
were ordering an MRI, systemic imaging, the type of surgery to be performed, patient 
choice and plastic surgery consultation (17). In terms of type of surgery, a study found 
that the mean time from consultation to lumpectomy was 22 (+16) days, the mean time to 
mastectomy was 37 (+29) days, and the mean time to mastectomy with reconstruction 
was 38 (+16) days (101). Other factors that were identified as influencing late receipt of 
surgery among Blacks were mode of detection, health insurance and tumor size (98). 
Radiotherapy 
 
Radiotherapy is recommended for stage I and II BrCa patients following BCS; 
however, Black women and other racial/ethnic minorities usually do not receive 
radiotherapy (25, 78, 91). Local recurrence of BrCa has been shown to be higher among 
patients that had BCS without concomitant radiotherapy (72, 102). Studies have shown 
that there were disparities in the receipt of radiotherapy by racial/ethnic minorities, as the 
odds of Black women experiencing radiation delay were 1.92 (95% C.I.: 1.55-2.37) 
compared to White women (78, 103). Black women with BrCa had a higher likelihood of 
receiving delayed radiotherapy after surgery compared to White women (98). Delay in 





Freedman et al. hypothesized some possible reasons for the racial disparities, 
including distance to treatment sites, inability to get time off work, childcare and limited 
transportation (78). Another possible reason that racial/ethnic minorities may not receive 
radiation therapy is that doctors may feel that the risks outweigh the benefits in older 
patients. However, after excluding older women (>69 years old) from their study, 
Freedman et al. still saw striking disparities affecting racial/ethnic minority groups, 
suggesting that there are other reasons for the disparities besides age (78). 
Adjuvant Hormone Therapy (AHT) 
 
Adjuvant hormonal therapy (AHT) has been shown to improve both short- and 
long-term survival among HRP BrCa patients worldwide, as it reduces BrCa mortality 
and reoccurrence by 33% and 40%, respectively. (104) Annually, over 100,000 women 
diagnosed with BrCa are classified as HRP, which has the potential of being cured (69, 
105) if BrCa patients commence and adhere to treatment with AHT. United States 
National Guidelines for the use of AHT recommends that women with HRP BrCa receive 
AHT for 5 years (85, 106, 107). AHT is a prescription oral medication, and studies show 
that current rates of adherence are between 50% and 75%, and most BrCa patients 
discontinue the medication within the first year after prescription (108-112).  
The advantages of AHT notwithstanding, 10-30% of eligible BrCa patients never 
start treatment with AHT, (113, 114) and many who start AHT never adhere to or 
complete the treatment, (111, 112, 115) leading to recurrence and increased mortality. 
(116) Specifically, a study in New Zealand showed that suboptimal usage of AHT led to 




compared to Whites. (117) However, the association between race and commencement of 
AHT is not well elucidated and appears incompletely studied and controversial; thus, 
further study is warranted.(6, 26) 
Assessment of AHT use 
There are various ways to assess use of AHT among BrCa patients. One method 
is to assess if a BrCa patient ever used AHT (6). Patients referred to as ever-users are 
those who have at least one pharmacy claim record for any AHT medication during the 
study period (6).  Determination of ever use of AHT can be done by utilizing records in 
the registry data or the pharmacy claims data, including claims for tamoxifen or 
aromatase inhibitors such as exemestane, letrozole and anastrozole (6, 69, 118-123).  
Another way to assess the use of AHT is to determine early/late initiation of AHT 
after a diagnosis is made (6). In this case, patients who received AHT within 12 months 
of diagnosis are categorized as early users, and those that started treatment with AHT 
after 12 months will be categorized as late users (6).  
A third mechanism to determine use of AHT is the medication possession ratio 
(MPR) (6, 69, 112, 114, 115, 124).  MPR here is defined as the AHT prescription supply 
per unit time (days) for the year following the start of AHT (or until data is censored by 
disenrollment). In order to calculate the MPR, the numerator is the total days covered by 
the medication (using total day supply) and the denominator is the number of days for 
which the supply is needed (69, 112, 114-116, 121-123). A ratio of more than 80% is 




Another method to assess AHT use is adherence, which is further divided into 
duration of treatment, persistence and consistent daily use of AHT (126). Adherence to 
prescribed AHT is the degree to which a patient’s behavior in taking AHT corresponds 
with the medical recommendation (126). Persistence is the time period for which a 
patient continues to fill prescriptions after the initial filling, and the interval between 
prescription refills is usually measured and reported (114, 125-127). Prescription rate has 
also been utilized to assess use of AHT and is estimated as a minimum of one pharmacy-




The recommendation from clinical trials is that adjuvant chemotherapy be 
initiated within 3 months after surgical intervention (54). Diagnosis-to-chemotherapy 
time was shown to be longer for Blacks compared to Whites, and this observed difference 
was shown to be higher among women that had their cancer care transferred from other 
health care providers to National Comprehensive Cancer Network (NCCN) institutions 
after the diagnosis was made (128). The racial disparity was also more marked among 
women that were on Medicare compared with women on commercial insurance (128).  
A study by Fedewa et al. showed that the mean time from surgery to receipt of 
adjuvant chemotherapy was 41 (+24) days (89). In this study, 85% and 96% of patients 
received adjuvant chemotherapy within 60 and 90 days, respectively, of surgery (89). The 
odds that a Black woman receives late treatment, defined as treatment after 60 days of 




race, other factors that contributed delayed receipt of chemotherapy were presence of 
comorbidities, the type of facility where the treatment was received, insurance status/type 
of the patient and stage at diagnosis (89). 
Survival Assessments in BrCa Patients 
 
There are different types of outcomes that have been studied in BrCa patients (57, 
129). Some of the most studied outcomes are overall survival (OS), BrCa-specific 
survival (BSS), BrCa progression-free survival (BPFS), (57, 129) and distant metastasis-
free survival (DMFS) (56). Usually, in cancer registry data, vital status and survival 
duration are relatively error-free, but the cause of death is sometimes not accurate, as 
some studies have shown that the underlying causes of death not coded as BrCa-related 
deaths may actually be associated with BrCa treatment–related deaths or are due to BrCa 
complications (57, 58). Some studies therefore have preferred OS rather than BSS (57, 
58). When it is not feasible to compare treatment types on the basis of OS, BPFS, which 
is the time from randomization to progression or death, has been utilized as an acceptable 
primary endpoint (129).  
Effects of Inadequate or Delayed Treatment on Survival among BrCa Patients 
 
A delay in receipt of BrCa treatment has been associated with reduction in BrCa 
survival (74-76). Delays of three or more months have been associated with low 5-year 
survival compared with patients who did not experience such a delay (41, 93). Delays 
that are less than 90 days have not been generally reported to affect survival in a negative 




primary treatment being surgery) using a cutoff point of 30 days did not find a 
statistically significant association between TPT and OS (92).  
Similar findings in North Carolina showed that diagnosis-to-treatment wait time 
did not have an association with OS when patients were diagnosed with early stage BrCa; 
however, the association was significant among BrCa patients that were diagnosed at late 
stages (8). In this study, the cutoff that to determine late receipt of treatment was 60 days 
(8). Women who had late-stage BrCa and received their first course of treatment at/after 
60 days after diagnosis had increases of 66% and 85% in their risk for all-cause and 
BrCa-specific mortality, respectively (8). Therefore, delays of greater than 90 days were 
significantly associated with poor survival in all patients, whereas delays of greater than 
60 days were statistically significant among late-stage BrCa patients alone (8, 92, 94). 
However, there was also a study that utilized 90 days as a cutoff point to 
determine delay in receipt of first definitive treatment for BrCa that did not find a 
significant association with OS (94). The reason given for the possible difference 
between this study and other studies that found significant associations with OS was the 
way in which the delay interval was calculated (94). Whereas other studies utilized onset 
of symptoms as the starting point, Brazda et al. utilized date of tissue diagnosis as the 
starting point (93, 94, 130). 
Effect of Diagnosis-to-Surgery Time on Survival 
 
Delay in breast cancer diagnosis-to-surgery time has been associated with 
disparities in breast cancer outcomes (9, 21, 93, 131, 132). BrCa patients who had 




with those who had surgery within 1-4 weeks (132). Poorer survival outcomes were 
associated with delays greater than 3-6 months among symptomatic women and 6 weeks 
among younger women (21, 93). 90% of women that had a diagnosis-to-surgery time of 
<2 weeks survived to 5 years, whereas 80% of women that had a diagnosis-to-surgery 
time of >6 weeks survived to 5 years (9).  
The negative effect of a diagnosis-to-surgery delay is more striking among Black 
women, who tended to have public or no insurance and were usually of lower SES (9, 
21).  When delays from diagnosis-to-surgery time were assessed using cutoffs less than 6 
weeks in some studies, mixed results were produced (21, 131, 133). A study that was 
carried out among TNBC patients showed that interval to treatment did not affect overall 
survival; however, there was a trend towards poor survival among patients with delays 
greater than 90 days (131). It has also been shown that longer diagnosis-to-chemotherapy 
time is associated with poorer survival outcome (54, 93). 
Effect of Diagnosis-to-Radiotherapy/Surgery-to-Radiotherapy Time on Survival 
 
The national guideline consensus by the NIH and ASCO states that BrCa patients 
who have high risk for locoregional recurrence should receive PMRT (47-52). Lack of 
receipt of radiation therapy following BCS has been shown to lead to increased mortality 
among BrCa patients (114, 134).  In a North Carolina study among Medicaid-enrolled 
women, higher mortality was observed among women who did not get radiotherapy after 
BCS (134). These women who did not get radiotherapy had higher odds all-cause and 
BrCa-specific mortality of 2.4 and 4.5, respectively (134). However, another study by Shi 




multivariate analyses (135). In terms of the effect of time from surgery to radiotherapy on 
survival, a study showed that BrCa patients with an interval greater than 7 months had a 
worse 6-year distant metastasis-free survival (56). 
Effect of Diagnosis-to-Chemotherapy Time on Survival 
 
BrCa patients who have delay in initiation of chemotherapy have significantly 
reduced 10-year survival (136). A study by Downing et al. utilized both traditional 
regression analyses and latent class analysis and found that women who had the longest 
wait to chemotherapy had the poorest 5-year survival (137). A meta-analysis conducted 
utilizing 7 studies showed that a 4-week increase in time to initiation of adjuvant 
chemotherapy was associated with significant decrease in OS and DFS (138). 
Effect of Diagnosis-to-AHT Time on Survival 
 
Inadequate adherence to AHT has been shown to reduce survival among BrCa 
patients (114, 126, 139). A study that assessed the effect of race on mortality outcomes 
noted a significant interaction between race and HRP BrCa cases in predicting mortality 
(41). The study further showed that Blacks with hormone receptor–negative (HRN) BrCa 
had a higher risk of death, with a hazard ratio of 4.0 compared to their White 
counterparts. Thus, hormone receptor status serves as an effect modifier in the 
relationship between race and mortality (41). Another study found that HRN BrCa 






Factors that Affect Diagnosis-to-Treatment Wait Times and Survival Outcomes 
 
(Independent predictors, potential confounders and potential effect modifiers) 
Independent predictors of longer diagnosis-to-surgery time that are 
socioeconomic in nature are advancing age, Black or Hispanic race, lack of 
insurance/Medicaid insurance, low level of education, living in urban areas, higher 
number of comorbidities and stage 0 and grade 1 disease (18). Facility-related 
independent predictors are high-volume facilities and research/academic facilities (18). 
Having to wait longer than 30 days to receive surgical intervention was a predictor of 
delay in the receipt of adjuvant chemotherapy greater than 60 days, meaning that one 
delay led to another delay (18). 
Age 
 
Most BrCa cases occur in women that are above the age of 49 years; however, 
BrCa patients that are younger have higher mortality and higher prevalence of factors 
leading to poor outcomes (65, 72). Women with BrCa that are younger than 36 years old 
are likely to have larger tumors, greater involvement of lymph nodes, higher stage 
disease, poorly differentiated tumors and HRN tumors (140).  
Factors that lead to poorer outcomes in younger women include larger-sized 
tumors, grade, involvement of lymph nodes, less HRP tumors, tumors with poorer grade, 
tumors with higher level of recurrences, higher S-phase fractions and higher likelihood of 
aneuploidy tumors (72, 140). All these factors lead to worse BrCa-specific and overall 




worse survival outcomes among younger women with BrCa are more prevalent among 
Black women than White women (72).  
Enrolment in Best Chance Network (BCN) Program 
 
The BCN is an early detection program in South Carolina for breast and cervical 
cancer (41, 141). Women that are eligible for this program are those that are aged 47-64 
years, residents of SC, underserved/underinsured or do not have insurance and are of low 
income (less than 200% of the Federal poverty level). This program provides free breast 
and cervical cancer screening and started because SC has one of the highest rates of 
uninsured women the United States (40, 41, 141). Recruitment into the BCN program is 
usually through active search by federally qualified health centers, the South Atlantic 
Division, media outlets and through outreaches carried out by the American Cancer 
Society. Women that are enrolled in BCN are usually of low socioeconomic status and 
are likely to experience treatment delays (41, 141).  
In St. Louis, Missouri, an evaluation of BrCa patients referred to the National 
Cancer Institute’s designated Comprehensive Cancer Center (NCI-CCC) showed that 
women that were referred from a scheme similar to the BCN called the safety net system 
experienced greater delays in treatment initiation compared to women that were referred 
from private healthcare systems (74-76). The women that were on the safety net systems 








There are multiple ways in which SES can contribute to BrCa disparities. One 
way is that those that are economically disadvantaged are unlikely to take advantage of 
screening efforts because of associated costs. This would lead to presentation of 
advanced BrCa among this group, thus creating large diagnostic delays and barriers to 
comprehensive care (65, 71). Another way that SES leads to racial BrCa disparities is that 
Blacks tend to disproportionately receive less of the treatments recommended by various 
guidelines, such as locoregional treatment, sentinel lymph node biopsy, reconstruction 
treatment for the breast, adjuvant radiotherapy and systemic adjuvant therapy, and they 
are less likely to participate in randomized clinical trials (71, 79, 142, 143).  
Interestingly, a study in North Carolina showed that poverty was a modifier in the 
effect of non-receipt of radiotherapy following BCS, as poor women who did not receive 
radiotherapy had 2.4 and 4.5 increased all-cause and BrCa-specific mortality, 
respectively, compared with non-poor women (134). This could be because poor women 
are likely to have more comorbidity, present with advanced-stage disease and forego 
annual surveillance mammography and are more likely to be geographically isolated 
from adequate care (134). 
One of the ways in which SES has been measured in past studies is utilization of 
neighborhood-level, area-level or Census –tract–level poverty (55, 57). In California, 
Haji-Jama et al. found that BrCa patients who lived in neighborhoods designated as poor 
have worse survival and that Blacks that lived in these poor neighborhoods had a 21% 




average difference between the annual income of Whites and Blacks in these poor 
neighborhoods was $14,575; hence, it is possible that Black uninsured women lacked the 
ability to cover out-of-pocket expenses associated with seeking care for BrCa (57, 144).   
Hormone Receptor Status and Receipt of Adjuvant Hormonal Therapy 
 
Beyond SES, the disproportionate burden of BrCa experienced by Blacks has also 
been partly attributed to biological factors, for which hormone receptor status can serve 
as a proxy (55, 65, 67, 105, 124, 145). The incidence rate of TNBC, which is a 
determinant of poor prognosis, has been shown to be much higher among Blacks 
compared to Whites (71, 79, 124, 145).  In addition, the incidence of BrCa among women 
aged 45 years and below, which is also associated with poor prognosis, is higher among 
Blacks compared to Whites (71, 72, 105).  
Additionally, studies have shown that after controlling for SES and stratifying by 
stage at diagnosis, there is a still residual disparity in the cancer burden that is 
unfavorable to Blacks when compared with Whites (65, 67). This points to the fact that 
there are biological factors that contribute to the Black-White disparity in BrCa 
outcomes. The role of biological factors has been buttressed by other studies that show 
that Black women of African descents (not born in the US) in Britain also have higher 
prevalence of TNBC compared with their White counterparts (71, 83, 146, 147). 
Insurance Type 
 
Insurance type has been shown to be a contributor to the differences in treatment 




additional 20 million US citizens obtained health insurance coverage; however, 
disparities in health insurance coverage still exist (71, 82). 24% of Blacks are currently 
uninsured, whereas that percentage is 8% among Whites (71, 82). A study by Smith et al. 
showed that 18% of BrCa patients with no health insurance/public health insurance had a 
delay of greater than 6 weeks in diagnosis-to-surgery wait time compared with only 10% 
of those with private health insurance (9). 
Stage at Diagnosis 
 
A greater proportion of Blacks are diagnosed with later-stage disease (148). The 
odds of presenting with late-stage disease among Blacks is 1.5-folds higher than among 
Whites (148). Blacks have a 30-60% higher likelihood of being diagnosed with a stage II-
IV BrCa when compared to Whites (79). 
Type of Surgery 
 
The scheduled type of surgery has also been found to influence the diagnosis-to-
treatment wait time (74, 128). It has been shown that women who were scheduled for 
breast reconstruction surgery experienced increased treatment delays (74, 128). In 
addition to experiencing delays from diagnosis-to-treatment wait times, these BrCa 
patients have a higher likelihood of having surgical complications, which may lead to 
further delays in the initiation of other adjuvant systemic therapies (74, 128, 149, 150). 
Marital Status 
 
Mosunjac et al. found that unmarried women with BrCa experienced greater 




was 70 days for married women and was 93 days for unmarried women; this difference 
was statistically significant (151). 
County (Rural versus Urban Status) 
 
Rural versus urban status of BrCa patients has been implicated as a factor that 
affects the distribution of late-stage diagnosis (148). Women that lived in non-
metropolitan counties had a higher likelihood of presenting with late-stage BrCa  
compared with those who lived in metropolitan counties (148). 
Mortality-to-Incidence Ratio (MIR) 
 
The MIR is a unique way to assess racial cancer disparities (5, 10). The MIR is an 
important indicator that offers additional useful information beyond what incidence and 
mortality rates alone can provide in a study (5, 38). Some studies have utilized MIR 
methodology to compare cancer rates (5, 11-13). Wagner et al. previously described 
racial cancer disparities and the potential geographical determinants of cancer by 
calculating, comparing and mapping MIRs throughout the entire state of Georgia (GA, 
United  States) and found that Blacks in GA had relatively more fatal cancers than Whites 
for all cancer sites evaluated (10). Sunkara et al. also demonstrated a strong linear 
relationship between the colorectal cancer MIR and health system rankings across the 
various countries evaluated (14). 
Mapping of MIRs across SC Department of Health and Environmental Control 
(DHEC) health regions has been utilized in past studies in SC (5, 38).  SC DHEC 




health programs. A sensitivity analysis described previously by Sunkara et al. (152) 
examined the effect of moving across different “denominator years” to vary with the 
alignment of the average incidence-to-mortality time interval. The sensitivity analysis 
used all combinations of sex and race for cancers involving all anatomic sites. It was 
shown that the lines describing the MIR remained parallel, with the rates generally 
remaining stable over time across eight different 5-year periods beginning in 1996. This 
analysis was performed using incidence data from the SC Central Cancer Registry 
(SCCCR) (152).  
As a ratio with the mortality rate as the numerator and the incidence rate as the 
denominator, the MIR takes on numeric values ranging from 0 to 1. Values closer to 0 
indicate more indolent cancers, whereas those closer to 1 indicate more aggressive 
cancers. The MIR, which has been shown to be highly insensitive to time-discordant 
incidence and mortality (152), does not take into account follow-up time and is not 
equivalent to Cox proportional hazards–type survival analysis, which is a truly 
multivariate technique that accounts for follow-up time. Similarly, the MIR cannot 
account for competing risk.  
Computing the MIR 
 
In past studies, in order to compare racial differences in MIRs in SC DHEC health 
regions, four categories of MIR were computed (5, 38). First, the MIR for a specific 
cancer of interest was computed for Whites nationally (93) (i.e., for the US as a whole 
from the United States Cancer Statistics at the Centers for Disease Control and 




limit of Category 2 was 10% higher than the reference; the upper limit of Category 3 was 
20% higher than the reference; and Category 4 consisted of MIRs >20% higher than the 
reference. This method of categorization and analysis was used previously by Hebert et 
al. and Babatunde et al. (5, 38) The defined categories of each DHEC health region were 
mapped by race using ArcGIS Version 10.1 (ESRI, Redlands, CA) .  
Importance of the MIR in Cancer Surveillance 
 
Using the MIR as a surveillance tool in a past study underscores the point that SC 
exhibits more extreme racial differences in cancer incidence, mortality and MIR than 
other states or the nation (30-37), and specifically, the MIR helped highlight regions 
where this disparity is highest (38). For example, in this past study, Regions 6 and 4 in 
SC have the highest MIR disparity, where the MIRs of Blacks are 3.1 and 3.0 times 
higher, respectively, than those of Whites. Regions 6 and 4 encompass the Pee Dee 
region, which is known for its lower socioeconomic status, rurality and being medically 
underserved (5). Additionally, in four of the 12 counties in the Pee Dee regions (Dillon, 
Lee, Marlboro and Williamsburg), over 40% of adults report a BMI of 30 or more (153). 
Similarly,  the percentage of adults aged 20 and over reporting no leisure-time physical 
activity was greater than 30% in seven counties (Chesterfield, Darlington, Dillon, Lee, 
Marion, Marlboro and Sumter) out the 12 counties in the Pee Dee region (153). Urban 
centers with major hospital systems such as Charleston (Region 7), Columbia (Region 3), 
Greenville and Spartanburg (Region 2) may be responsible for the relatively smaller MIR 




The MIR serves as a population-based approximation of fatality (1/survival) given 
incidence by stabilizing the incidence and mortality differences across cancer sites and 
racial groups (5, 10, 38). One of the advantages of MIR analyses lies in the fact that it 
gives researchers the opportunity to use combined data over many years with minimal 
data request protocol; this makes MIR estimates more stable (38). Data used for MIR 
analyses usually help mitigate problems associated with migration of patients in and out 
of a jurisdiction/state. This is because of the interjurisdictional exchange agreements 
between states to capture out-of-state deaths of residents. Also, MIR analyses usually 
involve a population-based study of the entire population of patients, whereby incidence 
and mortality data represent >94% of all cancer cases. Thus, the study is virtually devoid 
of selection bias, a common problem associated with such studies. Additionally, the MIR 
is cheap and easy to compute from existing relatively complete data. The MIR can be 
used as a surrogate measure for a more expensive and time-consuming survival studies 
(38).  
Drawbacks of the MIR Necessitating Need for a Sensitivity Analyses 
 
A main drawback of the MIR, however, is that there is no way to compute 
censoring and loss to follow up. It is also not possible to adjust for covariates such as 
treatment, comorbidities or individual socioeconomic status in the analysis. Another 
weakness is that the relationship between the numerator (mortality) and the denominator 
(incidence) may not be direct because persons diagnosed of with cancer may not die of 
cancer and persons who die after the diagnosis of cancer may survive for varying lengths 



























This study was a retrospective cohort study (2002 to 2009) that included data on 
all BrCa patients derived from linked files from the SCCCR and Office of Revenue and 
Fiscal Affairs (which maintains the administrative medical claims data for the South 
Carolina Public Employee Benefits plan and Medicaid). The study was exempt from IRB 
review by the University of South Carolina IRB. All newly diagnosed cases of cancers 
were collected by SCCCR, which is a population-based system in SC. Data in the 
SCCCR included information on demographics, diagnosis date, cancer location and 
histology, treatment and overall survival. (38) All incident cancer cases were required by 
law to be reported to SCCCR, a resource established with funding from an award from 
the National Program of Cancer Registries (NPCR) in 1994. Enabling legislation from 
the SC General Assembly was enacted in 1996. Data are collected by SCCCR on all 
cancers, both in-situ and invasive, from hospitals, pathology laboratories, freestanding 
treatment centers and physician offices. The only exceptions are in situ forms of cervical 
cancer and invasive forms of basal and squamous cell skin cancers of non-genital sites.  
The SCCCR from which we derived the data for this analysis has a history of 
receiving the highest/gold rating for data completeness (>94%), timeliness and data 




SCCCR is a member of the CDC National Interstate Data Exchange System (N-IDEAS), 
such that any member state may share resident incident cases with others to ensure the 
completeness of incident cancer data. Additionally, there was geocoding of all cancer 
cases and cancer deaths in the state of SC.  
The SC Revenue and Fiscal Affairs Office (RFA) is an independent agency that 
houses administrative claims data from both SC State Employee Health Plan and SC 
Medicaid plan members. The RFA developed a series of algorithms using various 
combinations of personal identifiers to create its own unique identifier, enabling 
statistical staff to “link across” multiple providers and settings.  Hence, it allowed for 
linkages while protecting the confidentiality of the client. The SC Revenue and Fiscal 
Affairs Office and SC Central Cancer Registry frequently work together to complete data 
linkage requests for researchers in SC. All BrCA cases between the time period of 2002 
to 2010 who met eligibility criteria (that could be ascertained from their files) were given 
to RFA. Then RFA matched to determine which cases linked and further met our 
eligibility criteria (that required claims data to ascertain).  This resulted in the 2155 cases.  
This resulting combined dataset was used to conduct all analyses. 
Data Linkage and Security 
 
Linkages were made with 3 personal identifiers: name, date of birth and social 
security number.  As per protocol, these linkages were performed by RFA in partnership 
with SCCCR.  Because of data security issues, only the final de-identified dataset was 
released to study personnel and investigators for analysis. The key to the de-identified 




the primary record. Once the de-identified data were received, the study data manager 
performed routine outlier and logic checks. Any improbable values were verified with 
RFA or SCCCR and rectified where possible. To create an analytic dataset, we utilized 
datasets from the RFA (Medicaid and State Health Plan), BCN and SCCCR to create an 
extensive look at breast cancer treatment in South Carolina for Black and White women. 
Data acquisitions were linked through the aforementioned departments by the RFA, and 
only a study participant number was assigned to each person for analysis by investigators. 
Because the final dataset was completely de-identified, the investigators have no linkages 
to the original identifiable patient contact information and will be referred to via a study 





For aim 1, the main predictor variable was race of the BrCa cases, dichotomized 
as Black or White. The main outcome variable was time from diagnosis to various forms 
of treatment, i.e., surgery, AHT, chemotherapy and radiotherapy. Outcome variables 
were treated as numeric variable (days) or dichotomized variables (early and late) 
depending on whether they met the assumptions for a linear model. Variables that were 
considered as covariates or effect modifiers are age, marital status, county of residence 
(whether rural or urban), year of diagnosis, hormone receptor status, enrolment in BCN 







For aim 2, the main predictor variable was race of the BrCa cases, dichotomized 
as Black or White. The main outcome variable was time until death. Variables that were 
considered as covariates or effect modifiers are age, marital status, county of residence, 
year of diagnosis, hormone receptor status, enrolment in BCN (dichotomized as yes or 
no), sta ge of BrCa at diagnosis and grade of BrCa at diagnosis. 
Outcome Variables. Overall and breast cancer mortality: We utilized vital status, 
total survival time, and BrCA cause of death (yes/no) for this investigation.  From cause 
of death information, we were able to examine both all-cause/overall mortality, as well as 
BrCa-specific mortality.            
For survival analyses, the main predictor variable was race stratified by region, 
categorized as Upstate, Midlands, Low Country and Pee Dee. Survival analyses were 
carried out in each of the four regions and ranked using hazard ratios. Possible covariates 
or effect modifiers are age, marital status, county of residence, year of diagnosis, 
hormone receptor status, stage of BrCa at diagnosis, grade of BrCa at diagnosis, race of 
the BrCa cases dichotomized as Black or White, receipt of AHT dichotomized as yes/no, 
early/late receipt of AHT, and BCN dichotomized as yes/no.  
Aim 3 
 
This study described BrCA disparities in SC among Blacks and Whites using 
MIRs by race for the four health regions and by 46 counties within SC. We proceeded to 
rank the four health regions by race from the worst to the best using MIRs. MIR were 




Community Access Network (SCAN) for 1996 to 2016 (county maps) and 2002 to 2010 
(regional maps). In order to compare racial differences in BrCa MIRs in the four SC 
DHEC health regions, seven categories (for county maps) of BrCa MIRs were defined. 
First, the MIR were computed for Whites nationally (93) (i.e., for the US from the United 
States Cancer Statistics at the Centers for Disease Control and Prevention) as a reference. 
The upper limit for Category 1 was the reference; the upper limit of Category 2 was 10% 
higher than the reference; the upper limit of Category 3 was 20% higher than the 
reference; the upper limit of category 4 was 30% higher than the reference; the upper 
limit of category 5 was 40% higher than the reference; the upper limit of category 6 was 
50% higher than the reference and Category 7 consisted of MIRs >50% higher than the 
reference. This method of categorization and analysis was adapted from a previous study 
by Hebert et al. and Babatunde et al. (5, 38) 




Overall goal: We assessed racial disparities in treatment delays among 
patients diagnosed with BrCa. 
Approaches of the dissertation research project: The main outcome variable 
were diagnosis-to-treatment time (overall and by various treatment modalities, i.e., 
surgery, AHT, chemotherapy and radiotherapy), which were defined as the interval 
between the date of diagnosis and the date of first treatment for the four forms of 
treatment. The main exposure variable was the patient’s race (White vs Black). Race will 




data collected by hospitals and providers. Student’s t-test with a significance level of 0.05 
were used to assess differences in diagnosis-to-treatment times by patient’s race. The 
outcome variables were checked for normality and other linearity assumptions. If 
linearity assumptions were met, a generalized linear model will be used to compute least-
square means and 95% C.I.s for each dependent variable (surgery wait time, AHT wait 
time, radiation wait time and chemotherapy wait time) comparing those Blacks with 
Whites after adjustment for age, marital status, county of residence, year of diagnosis, 
hormone receptor status, enrolment in BCN (dichotomized as yes or no), stage of BrCa at 
diagnosis and grade of BrCa at diagnosis. Observations with elevated studentized 
residuals and Cook’s D values were removed from the analyses.  
When linearity assumptions were not met, we dichotomized the four outcomes 
into early and late receipt of treatment using the cutoff as determined from the median in 
the univariate analyses of the outcome variables. When this latter option was used, we 
fitted a logistic regression model to compare early to delayed  receipt of treatments with 
the goal of identifying important predictors of treatment delay for each dependent 
variable (surgery, AHT, radiation and chemotherapy) comparing Blacks with Whites 
after adjustment for age, marital status, county of residence, year of diagnosis, hormone 
receptor status, enrolment in BCN (dichotomized as yes or no), stage of BrCa at 









Overall goal: Identification of patient- and neighborhood-level predictors of dissimilarity 
in BrCa-related survival among Blacks utilizing multilevel (state and regional) survival 
models among BrCa patients. 
Approaches of the dissertation research project:  
For aim 2, Kaplan-Meier survival curves were used to assess BrCa-specific and 
all-cause survival at the state and regional levels. The relationships between race, 
mortality rates, diagnosis-to-treatment times and all covariates will be assessed using the 
Cox proportional-hazards model. A backward elimination process was utilized to obtain 
the best model. Individual-level, (30) and health region–level (i.e., four health regions 
comprised of contiguous counties located in SC) (38) factors have been shown to make 
contributions to the pervading cancer disparities experienced by minority groups. A 
combination of geospatial methods and multilevel survival modeling helped to 
objectively identify individual-level and health region–level predictors of survival. The 
use of GIS and related spatial methodologies has the potential to identify 
environmental/neighborhood predictors of health outcomes, and this technique is 
increasing in popularity. (154, 155) Predictor variables/covariates that were considered 
with survival analyses are age, marital status, county of residence (urban or rural), year of 
diagnosis, hormone receptor status, enrolment in BCN (dichotomized as yes or no), stage 







Overall goal: To compare MIR methodology with survival methodology in assessing 
racial BrCa disparities over the eight-year period across the four health regions in SC.  
Rationale:  
Survival analysis: Overall survival rates was estimated using Kaplan-Meier 
techniques. 5-year and 12-year overall survival and BrCA specific survival were 
estimated and corresponding 95% confidence intervals were calculated. Cox Proportional 
hazard models were used to evaluate the impact of race on overall survival while 
adjusting for potential confounders.  
 
MIR: BrCa MIRs by race (Black vs. White) will be computed for years 2002-
2010. Years 2002 to 2010 will be utilized to mirror the years of registry data that were 
obtained for the survival analyses. The age-adjusted incidence and mortality rates will 
first be calculated using incidence and mortality data from SCCCR. MIRs will be 
stratified by race, specifically Blacks versus Whites. As a ratio with the mortality rate in 
the numerator and the incidence rate in the denominator, the MIR takes on values ranging 
from 0 to 1. Values closer to 0 indicate more indolent cancers, whereas those closer to 1 
indicate more aggressive cancers. The MIR, which has been shown to be highly 
insensitive to time-discordant incidence and mortality (152), does not take into account 
follow-up time and is not equivalent to Cox proportional hazards-type survival analysis, 




Computing the MIR 
 
This study described BrCA disparities in SC among Blacks and Whites using 
MIRs by race for the four health regions and by 46 counties within SC. We proceeded to 
rank the four health regions by race from the worst to the best using MIRs. MIR were 
computed from Cancer incidence and mortality data which were obtained from the SC 
Community Access Network (SCAN) for 1996 to 2016 (county maps) and 2002 to 2010 
(regional maps). In order to compare racial differences in BrCa MIRs in the four SC 
DHEC health regions, seven categories (for county maps) of BrCa MIRs were defined. 
First, the MIR were computed for Whites nationally (93) (i.e., for the US from the United 
States Cancer Statistics at the Centers for Disease Control and Prevention) as a reference. 
The upper limit for Category 1 was the reference; the upper limit of Category 2 was 10% 
higher than the reference; the upper limit of Category 3 was 20% higher than the 
reference; the upper limit of category 4 was 30% higher than the reference; the upper 
limit of category 5 was 40% higher than the reference; the upper limit of category 6 was 
50% higher than the reference and Category 7 consisted of MIRs >50% higher than the 
reference. This method of categorization and analysis was adapted from a previous study 
by Hebert et al. and Babatunde et al. (5, 38) 
Comparison of MIR and survival 
The health region–specific MIRs by race were compared with survival by race in 
each health region to see if the MIR is a true approximation of survival. The hypothesis is 
that the median survival time will be a mirror image of the MIR for each of the eight 




Systems software, version 9.2 (SAS Inc., Cary, NC). All hypothesis testing will be 2-
sided with a p<0.05 level of statistical significance.   
A study that I led in the past (38) utilizing MIRs as a proxy for survival under the 
supervision of my mentor showed that MIR helped highlight regions where endometrial 
cancer (EC) disparity was highest. For example, Regions 6 and 4 have the highest MIR 
disparity in EC, where the MIRs of Blacks are 3.1 and 3.0 times higher, respectively, than 
those of Whites. In SC, Regions 6 and 4 encompass the Pee Dee region, which is known 
for its lower socioeconomic status, rurality and being medically underserved (5). 
Additionally, in four of the 12 counties in the Pee Dee region (Dillon, Lee, Marlboro and 
Williamsburg), over 40% of adults report a BMI of 30 or more (153). Similarly,  the 
percentage of adults aged 20 and over reporting no leisure-time physical activity was 
greater than 30% in seven counties (Chesterfield, Darlington, Dillon, Lee, Marion, 
Marlboro and Sumter) out of the 12 counties in the Pee Dee region (153). Also in this 
study, (38) urban centers with major hospital systems such as Charleston (Region 7), 
Columbia (Region 3), Greenville and Spartanburg (Region 2) may be responsible for the 





RACIAL DISPARITIES AND DIAGNOSIS-TO-TREATMENT TIME 




A delay in the commencement of treatment has been hypothesized as one of the 
possible reasons for the higher mortality among Blacks despite lower incidence over the 
years. (3) Survival studies have shown that a treatment delay is associated with less 
favorable survival among BrCA cases. (3, 8, 9) Although the Black-White disparity in 
BrCA mortality is seen both at the national level and in SC, the disparity is of a higher 
magnitude in SC (30, 40, 41): mortality among White BrCA patients is 7% lower in SC 
compared to the national average and is 29% higher among Blacks in SC (30, 40, 41). 
Also, in SC, mortality from BrCA amongst Blacks is greater than 60% than that of 
Whites (5). Studies also show that Blacks experience worse mortality outcomes after 
matching for known prognostic factors, and this finding has persisted over time (42-45).   
The various forms of delay that Black women diagnosed with BrCA experience 
are related to diagnosis, (19) as well as time to surgery, (3, 20, 21) chemotherapy, (4, 22, 
23) adjuvant hormonal therapy, (24-26) and all forms of treatment combined. (27, 28) 




hospital type, (23) trust in oncologists and communication with physicians. (4) Delays in 
adjuvant therapy among BrCA patients have been shown to worsen survival (18, 29) and 
increase patient anxiety. (18) 
Although various studies in other states consistently show that Black women with 
BrCA experience delays in receipt of surgery, chemotherapy, AHT and radiation, (3, 4, 
19-23, 27, 28) this has not been examined in SC, which has a high representation of 
minority and rural populations. SC has well-documented inter-racial differences in cancer 
incidence and mortality (30-38). In addition, the possible factors that affect racial 
disparity in treatment delays in SC have not been examined.  
The aim of this study was to assess racial disparities in BrCA treatment time in 
South Carolina (SC) by comparing diagnosis-to-treatment times for the various forms of 
treatment in Blacks and Whites with BrCA and to assess related effect modifiers. We 
hypothesize that the diagnosis-to-treatment wait time is higher among Blacks compared 





This is a retrospective cohort study (2002 to 2010) that included data on all BrCA 
patients derived from linked files from the SC Central Cancer Registry (SCCCR) and 
Office of Revenue and Fiscal Affairs (which maintains the administrative medical claims 
data for the South Carolina Public Employee Benefits plan and Medicaid). The dataset 




South Carolina’s IRB. All newly diagnosed cancer cases are collected by SCCCR, which 
is a population-based cancer registry in SC. Data in the SCCCR include information on 
demographics, diagnosis date, cancer location and histology, treatment and overall 
survival. (38)  
The SCCCR has a history of receiving the highest/gold rating for data 
completeness (>94%), timeliness and data quality from the North American Association 
of Central Cancer Registries and NPCR. SCCCR is a member of the CDC National 
Interstate Data Exchange System (N-IDEAS), such that any member state may share 
resident incident cases with others to ensure the completeness of incident cancer data. 
Additionally, there is geocoding of all cancer cases and cancer deaths in the state of SC.  
The SC Revenue and Fiscal Affairs Office (RFA) developed a series of 
algorithms using various combinations of personal identifiers to create its own unique 
identifier, enabling statistical staff to “link across” multiple providers and settings.  
Hence, it allows for linkages while protecting the confidentiality of the client. All BrCA 
cases between the time period of 2002 to 2010 who met eligibility criteria (that could be 
ascertained from their files) were given to RFA. Then RFA matched to determine which 
cases linked and further met our eligibility criteria (that required claims data to ascertain).  
This resulted in the 2155 cases.  This resulting combined dataset was used to conduct all 
analyses. 
Because of data security issues, only the final de-identified dataset was released to 
study personnel and investigators for analysis. The key to the de-identified dataset was 
retained by RFA if further data clarifications are needed from the primary record. Once 




checks. Any improbable values were verified with RFA or SCCCR and rectified where 
possible. To create an analytic dataset, we utilized datasets from the RFA (Medicaid and 
State Health Plan), Best Chance Network (BCN) and SCCCR to create an extensive look 
at BrCA treatment in South Carolina for Black and White women. The BCN is an early 
detection program in South Carolina for breast and cervical cancer (41, 141). Women that 
are eligible for this program are those that are aged 47-64 years, residents of SC, 
underserved/underinsured or do not have insurance and are of low income (less than 
200% of the Federal poverty level). 
Inclusion and Exclusion Criteria 
To qualify for inclusion in the analytic sample, the BrCA cases were those 
diagnosed as a first primary cancer between 2002 and 2010, had a form of insurance 
(either Medicaid or state health plan) at the time of diagnosis and had 36 months of 
continuous eligibility on the insurance. This was to ensure that treatment data was 
available for at least 36 months post diagnosis for each case. 
Variables 
 
The main predictor variable was race, dichotomized as Black or White. Race 
variable was self-reported as determined by the SCCCR records. The main outcome 
variable was time from diagnosis to receipt of first treatment for various forms of 
treatment, i.e., surgery, AHT, chemotherapy and radiotherapy. The first treatment 
received was determined and the number of days from diagnosis to the treatment 
modality was also determined. New variables designated diagnosis-to-treatment time for 




as numeric because records met the assumptions for a linear model using skewness and 
kurtosis of -2 to +2 when assessed by race.  
The outcome variable for chemotherapy, radiotherapy and surgery were 
dichotomized variables (early and late) because they did not meet the assumptions for 
linear models. The cut-off for dichotomization was based on the median for the 
distribution which was 22, 60, and 60 for surgery, chemotherapy and post-surgery 
radiotherapy respectively. Variables that were considered as covariates or effect 
modifiers were age, marital status, urban vs. rural designation (based on rural urban 
commuting codes/RUCA 2003), year of diagnosis (2002-2004, 2005-2007, 2008-2010), 
hormone receptor status (positive or negative), enrollment in BCN (dichotomized as yes 
or no), stage of BrCA at diagnosis (insitu, local, regional, or distant), grade of BrCA at 
diagnosis (well differentiated, moderately differentiated, poorly differentiated and 
undifferentiated) network distance to health care provider (in miles), definitive surgery 
type (lumpectomy or mastectomy), early/late surgery (early or late), and insurance 
provider (provider 1 or provider 2). One of the health insurance provider categories was 
Medicaid, while the other one was private (State Employee Health Plan); the specific 
payer source was not identified in the analytic dataset as per data use agreements 
specified by the payers. 
Analysis  
A generalized linear model was used to compute least-square means and 95% CIs 
for AHT (dependent variable that met linear assumptions) comparing Blacks with Whites 
after adjustment for age, urban versus rural designation, year of diagnosis, hormone 




diagnosis, and distance to providers. In assessing the relationship between race and time 
to AHT, we assessed for the presence of effect modifiers and marital status, being 
enrolled in BCN, late surgery and insurance providers were identified as effect modifiers: 
the multivariable generalized linear model therefore was stratified by the effect modifier 
variables. 
The variables that did not meet linearity assumptions (chemotherapy, radiotherapy 
and surgery), were dichotomized into early and late receipt of treatment using 22 days for 
surgery, 60 days for chemotherapy and post-surgery radiation. Two-way interactions 
were assessed between the all predictor variables and race. There was statistically 
significant interaction between race and marital status, race and urbanicity, and race and 
distance. The multivariable logistic model was stratified by the effect modifier variables 
and each model was adjusted for age, year of diagnosis, hormone-receptor status, stage, 
grade, and being in BCN. 
In assessing the relationship between race and time to post-surgery radiation, the 
identified effect modifiers were age, hormone-receptor status and insurance provider. The 
multivariable logistic model was stratified by the effect modifier variables and each 
model was adjusted for marital status, urban status, year of diagnosis, stage, grade, 
distance to providers and early/late receipt of surgery. In assessing the relationship 
between race and time to chemotherapy, the identified effect modifiers were urban status 
and early/late surgery. The multivariable logistic model was stratified by the effect 
modifier variables and each model was adjusted for age, marital status, diagnosis year, 






Descriptive statistics for this study sample are shown in Table 1.  Overall, there 
were 2155 cases of BrCA patients of which the majority were Whites (1557, 72.25%). In 
bivariate analyses, there were significant differences between Blacks and Whites in age, 
rural/urban status, year of diagnosis, hormone receptor status, cancer grade, cancer stage 
and insurance provider. Blacks were more likely to be in age group 45-54 (45.99%) while 
whites were more likely to be in age group 55-64 years (41.88%). Blacks were more 
likely to be unmarried (57.17%) compared to Whites (29.95%). The proportion of Whites 
that live in urban area (79.13% vs 67.22%) and have hormone receptor positive cancer 
(81.03% vs 68.89%) is higher among whites compared to blacks. More blacks were 
participants in BCN compared to Whites (9.87% compared with 3.85%). 
Table 2 presents diagnosis to hormone treatment times by marital status, being in 
BCN, early surgery and insurance provider. Multivariable generalized linear model 
regression analysis showed that the least square means from diagnosis to surgery were 
statistically increased among Blacks that were not married (54 days), Blacks that were 
not on BCN (36 days), Blacks that had late surgery later than 30 days after diagnosis (42 
days), Blacks that had surgery later than 60 days after diagnosis (63 days) and Blacks that 
were on insurance provider 1 (46 days) adjusting for age, diagnosis year, hormone-
receptor status, stage, grade, urban status, and distance to provider.   
Multivariable logistic regression that adjusted for 8 variables (age, year of 
diagnosis, hormone receptor status, cancer stage, cancer grade, being in BCN, definitive 




1.96 (95% CI: 1.38-2.79) among unmarried black women compared with unmarried 
white women; 1.89 (95% CI: 1.32-2.71) among blacks who lived <=10 miles to health 
providers compared to whites who lived <=10 miles; and 1.40 (95% CI: 1.08-1.82) 
among blacks who live in urban areas compared with white women who lived in urban 
areas (Table 3). 
Table 4 presented the results of race by late receipt of post-surgery radiation 
stratified by age, hormone receptor status and insurance provider in which each model 
adjusted for marital status, urban status, diagnosis year, stage, grade, distance, definitive 
surgery type and receipt of early/late surgery. The only significant finding upon 
multivariable modeling was that black women were less likely to receive late post-
surgery radiation (OR: 0.30; CI: 0.10-0.93) compared to white women which implies that 
the odds of white women with hormone receptor negative BrCA receiving late post-
surgery radiation was 3.3 (CI: 1.07-10.28).  
Table 5 presented the results of race by late receipt of chemotherapy stratified by 
urban status and late/early surgery. Each model adjusted for age, marital status, diagnosis 
year, stage, grade, distance, insurance provider and definitive surgery type. Multivariate 
analysis did not show any significant finding. 
 
Discussion 
This study demonstrated that there was a longer diagnosis-to-treatment time for 
all treatment modalities for Blacks when compared with Whites. Late receipt of AHT was 




the BCN. We also found that late receipt of surgery was higher among blacks that were 
unmarried, lived in urban areas and those who lived less than 10 miles to their health care 
provider. The only sub-group where whites had a later receipt of treatment was for post-
surgery radiation among hormone receptor negative BrCA patients. In addition to 
showing that there were longer diagnosis-to-treatment time in which has been 
demonstrated from previous studies, (18, 22, 26, 74, 128) we were able to add the 
following to the racial disparity discussion: the impact of being unmarried, living in 
urban areas, enrolment in BCN, and distance on late receipt of treatment. This study also 
showed the positive relationship between late receipt of surgery and time to AHT 
demonstrating that those who are late to receive one form of treatment are likely to be 
late at the receipt at other forms of treatment. The use of the findings in this paper has the 
potential to further enhance the understanding of navigation of health care process and 
strengthen navigation efforts aimed at linking women with BrCA to care especially 
among blacks thereby reducing racial disparities. 
In analysing the longer diagnosis-to-treatment time in receipt of AHT, this study 
had a cohort that contained patients on Medicaid and patients on a private payor health 
plan which made the findings more representative compared with previous studies that 
was among Medicaid only or private insurance only and which had different findings in 
racial disparities (6, 26). These previous studies showed that the association between race 
and commencement of AHT is not well elucidated and appears to be incompletely 
studied and controversial; thus, our work provided a further understanding of the 
relationship. In North Carolina (NC), statistically significant racial disparity in 




and this racial disparity was more pronounced among the subpopulation of patients that 
did not receive chemotherapy. (26) However, in a previous study in SC, there was no 
racial difference found between Blacks and Whites in the commencement and early use 
of AHT, but further analysis showed that receipt of chemotherapy/radiation was 
independently associated with commencement/early use of AHT. (6) In the study 
described above in NC, the BrCA cases were privately insured (26); however, in the 
previous study in SC (6), the BrCA cases were on Medicaid insurance. Because our study 
had both groups of insurance providers, it provided a further understanding showing that 
racial disparities existed in receipt of AHT with blacks entering care at least about 17 
days later after adjustments were made for age, year of diagnosis, stage, grade, urban 
status and distance to provider. 
A study that used three cutoff points (30, 60, 90 days) to define a diagnosis-to-
surgery delay showed that Black women were more likely to experience delays compared 
to White women, and this association was independent of health insurance status, age at 
diagnosis and cancer stage at diagnosis (46). Additionally, studies have shown that after 
controlling for socio-economic status and stratifying by stage at diagnosis, there is still 
residual disparity in the cancer burden that is unfavorable to Blacks when compared with 
Whites (65, 67). Our study provided an additional insight into this topic by assessing 
other factors that influence a longer diagnosis-to-treatment time for surgery apart from 
health insurance, age at diagnosis and cancer stage at diagnosis (21). Our study showed 
that unmarried black women were more likely to have a longer diagnosis-to-treatment 
time in receipt of surgery and AHT. Our finding is like that of Mosunjac et al. which 




breast conserving surgery compared to married women (151). The mean time to BCS was 
70 days for married women and was 93 days for unmarried women; this difference was 
statistically significant (151). Our study also added to the literature with our finding that 
among women who lived in urban areas and who lived less than 10 miles to their health 
care providers, black women were likely to receive late surgery.  
The diagnosis-to-treatment interval is an important quality measure that is 
recognized by the National Accreditation Program for Breast Centers (NAPBC), the 
American Society of Breast Surgeons (ASBS) and the National Quality Measures for 
Breast Care (NQMBC) (94-96). The NAPBC, ASBC and NQMBC all serve to validate 
BrCA care rendered by hospitals (94-96). Although, there has been no formal agreement 
on what constitutes an acceptable delay in terms of quality of BrCA care measures (94-
96), our study demonstrated racial disparities in diagnosis to treatment in the receipt of 
surgery and AHT. Another reason that the diagnosis-to-treatment wait time is important 
is that studies have shown one of the most overwhelming, distressing and anxiety-
producing periods for BrCA patients is the waiting time between an abnormal 
mammogram and treatment initiation (94, 97). Our study therefore helped to identify 
subgroups of BrCA patients that may benefit from more intensive navigation to care in 
order to shorten the diagnosis-to-treatment times for various BrCA patients. 
Our finding that late surgery predicted late receipt of AHT is similar to previous 
studies where having to wait longer than 30 days to receive surgical intervention was a 
predictor of longer diagnosis-to-treatment time in the receipt of adjuvant chemotherapy 
greater than 60 days, meaning that one delay led to another delay (18). This is a finding 




need to be planned to link people who have already experienced one form of delay along 
the care continuum, so they do not continue to be delayed in other forms of treatment that 
has the potential to enhance survival.  
Our findings show that Blacks who were not enrolled in the BCN experienced a 
longer diagnosis-to-treatment time in receipt of surgery. The BCN is an early detection 
program in South Carolina for breast and cervical cancer (41, 141). Women that are 
eligible for this program are those that are aged 47-64 years, residents of SC, 
underserved/underinsured or do not have insurance and are of low income (less than 
200% of the Federal poverty level). This program provides free breast and cervical cancer 
screening and started because SC has one of the highest rates of uninsured women the 
United States (40, 41, 141). Recruitment into the BCN program is usually through active 
search by federally qualified health centers, the South Atlantic Division, media outlets 
and through outreaches carried out by the American Cancer Society. Women that are 
enrolled in BCN are usually of low socioeconomic status and are likely to experience 
longer diagnosis-to-treatment time (41, 141). In St. Louis, Missouri, an evaluation of 
BrCA patients referred to the National Cancer Institute’s designated Comprehensive 
Cancer Center (NCI-CCC) showed that women that were referred from a scheme similar 
to the BCN called the safety net system experienced longer diagnosis-to-treatment time in 
treatment initiation compared to women that were referred from private healthcare 
systems (74-76). The women that were on the safety net systems also had a higher 
likelihood of being diagnosed with advanced-stage BrCA (74-76). Since, our findings 
showed that there is a longer diagnosis-to-treatment time in receipt of AHT between 




BCN, it therefore suggests that, perhaps the BCN program in SC is helping to close the 
racial disparity gap between Whites and Blacks or those who are on BCN have other 
factors that is driving the racial disparities. This will benefit from future studies. 
One strength of this study is the availability of a wide range of effect modifiers 
and covariates that were utilized in the analysis. To our knowledge, this is the first study 
that assessed all 4 treatment modalities among both privately and publicly insured 
patients using both multivariate logistic regressions and multivariate generalized linear 
models (depending on distribution of outcome data) with specific emphasis on assessing 
effect modifiers in SC, which has a high representation of minority and rural populations. 
Our study was also able to analyze the role of distance to health care provider in late 
receipt of treatment. Limitations of this study include inability to study biological factors 
that contribute to the Black-White disparity in BrCA outcomes. The role of biological 
factors has been buttressed by other studies that show that Black women of African 
descents (not born in the US) in Britain also have higher prevalence of triple negative 
BrCA compared with their White counterparts (71, 83, 146, 147). 
In conclusion, late receipt of AHT was higher among blacks that were unmarried, 
received late surgery, and not a participant in BCN. We also found that late receipt of 
surgery was higher among blacks that were unmarried, lived in urban areas and those 
who lived less than 10 miles to their health care provider. There is a longer diagnosis-to-
treatment time in receipt of AHT between blacks and white that are not on BCN but no 
difference between blacks and white on BCN, it therefore suggests that, perhaps the BCN 
is helping to close the racial disparity gap between whites and blacks or those who are on 




being on BCN and diagnosis-to-treatment time in receipt on AHT will benefit from future 
studies as it will be important to understand the reason for the longer time among those 
not on BCN. To improve overall timely receipt of AHT, efforts need to be directed at 
Black BrCA patients that are not married, not on BCN and received late surgery. To 
improve overall timely receipt of surgery, efforts need to be directed at Black BrCA 




















Table 4.1 Summary of patients’ characteristics by race 
  N (%) N (%) N (%)  











 51.20(7.20) 51.60(6.99) 50.17(7.63) <0.01 
      
Age categories Under 45 
years old 
386(17.91) 256(16.44) 130(21.74) <0.01 
 45-54 years 
old 
924(42.88) 649(41.68) 275(45.99)  
 55-64 years 
old 
845(39.21) 652(41.88) 193(32.27)  
      
Marital status Not married 751(34.85) 436(29.95) 315(57.17) <0.01 
 Married 1256(58.28) 1020(70.05) 236(42.83)  
      
Rural/Urban 
status 
Urban 1634(75.82) 1232(79.13) 402(67.22) <0.01 
 Rural 521(24.18) 325(20.87) 196(32.78)  
      
Year of 
diagnosis 
2002-2004 611(28.35) 452(29.03) 159(26.59) 0.02 
 2005-2007 693(32.16) 518(33.27) 175(29.26)  
 2008-2010 851(39.49) 587(37.70) 264(44.15)  
      
Hormone 
receptor status 
Positive 926(42.97) 709(81.03) 217(68.89) <0.01 
 Negative 264(12.25) 166(18.97) 98(31.11)  
      
Stage at 
Diagnosis 
In-situ 422(21.72) 299(19.34) 123(20.78) 0.68 
 Local 1013(47.01) 741(47.93) 272(45.95)  
 Regional 657(30.49) 470(30.40) 187(31.59)  
 Distant 46(2.13) 36(2.33) 10(1.69)  
      
Cancer grade I 392(18.19) 300(21.29) 92(16.76) <0.01 
 II 785(36.43) 608(43.15) 177(32.24)  
 III 749(34.76) 479(34.00) 270(49.18)  




      
Best Chance 
Network 
Yes 119(5.52) 60(3.85) 59(9.87) <0.01 
 No 2036(94.48) 1497(96.15) 539(90.13)  
      
Insurance 
provider 
1 1640(76.10) 1285(82.34) 358(59.87) <0.01 





 7.25+17.00 7.19+18.09 7.44+13.40 0.79 






 19.89+23.54 19.99+25.03 19.60+19.11 0.72 






 18.64+18.54 18.19+18.30 19.75+19.11 0.17 



















Figure 4.1: Adjusted least square means for diagnosis to hormone treatment 
showing increase of 17 days among blacks compared to whites 
*p=<0.01 and Adjusted for age at diagnosis, diagnosis year, hormone-receptor status, 











































Table 4.2 Diagnosis-to-hormone treatment times stratified by BCN**, marital 
status*, early/late surgery and insurance provider 
 LSM (95% C.I.) LSM (95% C.I.) 
 Married (Yes) Married (No) 
White 190.08 166.42 
Black 210.11 213.01 
Black-White 20.03 46.59 
% Increase 10.54 28.00 
p-value 0.19 <0.01 
   
 BCN (Yes) BCN (No) 
White 173.63 153.78 
Black 175.85 186.24 
Black-White 2.22 32.46 
% Increase 1.28 21.11 
p-value 0.93 <0.01 
   
 Surgery 30 (Early) Surgery 30 (Late) 
White 154.39 169.94 
Black 178.76 211.47 
Black-White 24.37 41.53 
% Increase 15.78 24.43 
p-value 0.07 0.01 
   
 Surgery 60 (Early) Surgery 60 (Late) 
White 165.53 158.91 
Black 187.91 221.75 
Black-White 22.38 62.84 
% Increase 13.52 39.54 
p-value 0.06 0.01 
   
 Insurance provider 1 Insurance provider 2 
White 160.23 188.27 
Black 206.09 189.20 
Black-White 45.87 0.93 
% Increase 28.63 0.49 
p-value <0.01 0.96 
*All models adjusted for age at diagnosis, diagnosis year, hormone-receptor status, stage, 
grade urban status and distance to providers. 






Table 4.3 Racial disparities among breast cancer patients and the odds of late 
receipt of surgery stratified by marital status, urban status and distance 
Charact
eristic 










Overall   No (%) No (%) OR (CI) OR (CI) 
 White 1470(72.02) 700(47.62) 770(52.38) Reference Referenc
e 




Married       
Yes White 965(80.89) 463(47.98) 502(52.02) Reference Referenc
e 




No White 409(57.93) 187(45.72) 222(54.28) Reference Referenc
e 






      
Rural White 308(62.47) 160(51.95) 148(48.05) Reference Referenc
e 




Urban White 1162(75.06) 540(46.47) 622(53.53) Reference Referenc
e 






      
<=10mil
es 
White 526(70.79) 283(53.80) 243(46.20) Reference Referenc
e 






White 831(72.89) 385(46.33) 446(53.67) Reference Referenc
e 




*Models adjusted for age, diagnosis year, hormone-receptor status, stage, grade and 





Table 4.4 Racial disparities among breast cancer patients and the odds of late 
receipt of post-surgery radiation stratified by age, hormone receptor status, best 




Race Total Early receipt  
(<60 days) 
675(48.67%) 









  No (%) No (%) OR (CI) OR (CI) 
 White 995(71
.74) 







       
Age       
<45 White 171(66
.80) 






















































       
Insura
nce 
























* Models adjusted for marital status, urban status, diagnosis year, stage, grade, distance, 





































Table 4.5 Racial disparities among breast cancer patients and the odds of late 






Early receipt  
(<60 days) 
556(51.44%) 























       
Rural/
Urban 



























       
Surger
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* Models adjusted for age, marital status, diagnosis year, stage, grade, distance, insurance 









ASSESSMENT OF RACIAL DISPARITIES IN MORTALITY AMONG 




Statistics over the past 20 years in the United States have shown higher mortality 
rates among Blacks with breast cancer (BrCA) compared to Whites despite lower 
incidence of BrCA among Blacks.(1-4) The need to study disparities on survival among 
BrCA patients in SC is particularly important because Black-White disparity in BrCA 
mortality is of a higher magnitude in SC;(30, 40, 41) mortality among White BrCA patients 
is 7% lower in SC compared to the national average and is 29% higher among Blacks in 
SC.(30, 40, 41) Also, in SC, mortality from BrCA amongst Blacks is greater than 60% than 
that of Whites.(5) Studies also show that Blacks experience worse mortality outcomes 
after matching for known prognostic factors, and this finding has persisted over time.(42-
45) 
Factors that have been shown to influence BrCA survival are age, enrolment in 
best chance network, socioeconomic status, hormone receptor status, health insurance 
type, stage at diagnosis, type of surgery, complications of surgery, marital status and 




151) This study will add to existing body of literature on racial disparities BrCA-specific 
survival (BSS),(56) and overall survival (OS).(57, 58) Assessment of survival differences in 
this study by regions in SC has not been studied before. The aim of this study was to 
describe the breast cancer-specific and overall survival in SC, as well as by the four 
health regions and to assess the factors (confounders and effect modifiers) affecting 
survival among Black and Whites in SC overall. We hypothesize that treatment and 
mortality outcomes will be worse for Blacks who live in Pee Dee, which are 
characterized by lower socioeconomic status, and will be better in Midlands and Low 
Country because of the major hospital systems available in these regions. 
Methods 
Data Source 
This was a retrospective cohort study (2002 to 2010) that included data on all 
BrCA patients derived from linked files from the SCCCR and Office of Revenue and 
Fiscal Affairs (which maintains the administrative medical claims data for a private payor 
plan and Medicaid). The study was exempt from IRB review by the University of South 
Carolina IRB. All newly diagnosed cases of cancers are collected by SCCCR, which is a 
population-based system in SC. Data in the SCCCR include information on 
demographics, diagnosis date, cancer location and histology, treatment and overall 
survival.(38) All incident cancer cases are required by law to be reported to SCCCR, a 
resource established with funding from an award from the National Program of Cancer 




The SCCCR from which we derived the data for this analysis has a history of 
receiving the highest/gold rating for data completeness (>94%), timeliness and data 
quality from the North American Association of Central Cancer Registries and NPCR. 
SCCCR is a member of the CDC National Interstate Data Exchange System (N-IDEAS), 
such that any member state may share resident incident cases with others to ensure the 
completeness of incident cancer data. A cohort of 2,155 patients from the SCCCR with a 
diagnosis of female breast cancer from 2002 to 2010 was created. This cohort was linked 
to the same patients in the SC State Employee Health Plan and Medicaid datasets. The 
resulting combined dataset were used to conduct all analyses.  
Data Linkage and Security 
Linkages were made with 3 personal identifiers: name, date of birth and social 
security number. These linkages were performed by RFA in partnership with SCCCR. 
Because of data security issues, only the final de-identified dataset was released to study 
personnel and investigators for analysis. The key to the de-identified dataset was retained 
by RFA in the event that further data clarifications were needed from the primary record. 
Once the de-identified data were received, the study data manager performed routine 
outlier and logic checks. Any improbable values were verified with RFA or SCCCR and 
rectified where possible. To create an analytic dataset, we utilized datasets from the RFA 
(Medicaid and State Health Plan), BCN and SCCCR to create an extensive look at breast 
cancer treatment in South Carolina for Black and White women. Data acquisitions were 
linked through the aforementioned departments by the RFA, and only a study participant 
number was assigned to each person for analysis by investigators. Because the final 




identifiable patient contact information and will be referred to via a study participant 
number only.  
Variables 
Exposure Variable: The main exposure variable was race of the BrCA cases, 
dichotomized as Black or White. Variables that were considered as covariates or effect 
modifiers were age, marital status, county of residence, year of diagnosis, hormone 
receptor status, enrollment in BCN (dichotomized as yes or no), stage of BrCA at 
diagnosis and grade of BrCA at diagnosis. 
Outcome Variables: Overall and breast cancer mortality. We utilized vital 
status, total survival time, and BrCA cause of death (yes/no) for this investigation. From 
cause of death information, we were able to examine both all-cause/overall mortality, as 
well as BrCA-specific mortality.  
Exploratory Data Analysis: Kaplan-Meier survival curves were used to explore 
5-year and 12-year survival for BrCA-specific and all-cause survival at the state and 
regional levels. This was also stratified by race at the state and regional levels. Log rank 
test was used to assess the Kaplan-Meier plot with respect to race which was the main 
exposure. To test for adequacy of proportional hazard (PH) model, we graphically 
inspected whether the log-log survival (lls) curve were parallel with respect to the 
exposure of interest (race). The PH model was satisfied as the curves were parallel. Each 
exposure variable was tested utilizing the Schoenfeld Residual to ascertain the adequacy 




Assessment of interactions: In assessing the relationship between race and 
mortality, interactions were assessed.  Statistically significant interactions were noted 
between race and marital status; race and urbanicity; race and region; race and BCN. The 
analyses that assessed factors that influence disparity in mortality were therefore 
stratified by these four variables.  
Fitting the best model in each stratum: In each stratum, the relationships 
between race and mortality (breast-cancer specific and all-cause) were assessed by fitting 
the best Cox PH model through backward elimination starting with all potential 
covariates like age, year of diagnosis, hormone receptor status, enrollment in BCN 
(dichotomized as yes or no), stage of BrCA at diagnosis and grade of BrCA at diagnosis. 
Results 
Descriptive statistics for this study sample are shown in Table 1. Overall, there 
were 2155 cases of breast cancer patients of which the majority were Whites (1557, 
72.25%). In bivariate analyses, there were significant differences between Blacks and 
Whites in age, rural/urban status, year of diagnosis, hormone receptor status, cancer 
grade, cancer stage and insurance provider. Blacks were more likely to be in age group 
45-54 (45.99%) while Whites were more likely to be in age group 55-64 years (41.88%). 
Blacks were more likely to be unmarried (57.17%) compared to Whites (29.95%). The 
proportion of Whites that live in urban area (79.13% vs 67.22%) and have hormone 
receptor positive cancer (81.03% vs 68.89%) is higher among Whites compared to 





Figure 1 presents the Kaplan Meier plots of 12-year BrCA-specific mortality 
among Blacks and Whites in the state of SC and in Low Country region. There was 
statistically significant difference between Blacks and Whites in the state overall; 
however, among the 4 health regions, only the Low Country region had statistically 
significant difference with mortality higher among Blacks. This difference is seen as 
early as 3 years and it continues to widen till 12 years. Figure 2 is the all-cause mortality 
variant of Figure 1 and the findings are similar to that of Figure 1. 
Table 2 shows the 5- and 12- year survival proportion for BrCA-specific and all-
cause mortality among Blacks and Whites in the entire state of SC and also by the 4 
health regions in SC. Table 2 shows that both the 12- year BrCA specific survival 
(91.3%) and the 12-year overall survival (89.3%) were highest in Low Country region, 
however, the black-white disparity was also higher in this region. As seen in Figure 1 and 
2, Table 1 also shows that there is significant increase in mortality among Blacks relative 
to Whites in the data that examined the state of SC and in the Low Country region of the 
state. 
The crude hazard ratio of mortality among Blacks compared with Whites was 
1.42 (1.03, 1.95) for overall survival and 1.49 (1.04, 2.14) for BrCA specific survival 
(data not shown). Table 3 presents the Cox proportional hazard models. Multivariable 
Cox proportional hazard that adjusted for cancer stage showed that the hazard ratio of 
mortality was 3.45 (1.64,7.25) among Black women who lived in Low Country region of 
the state compared with White women who lived in Low Country region of the state 
when all-cause mortality was examined. A similar hazard ratio of mortality of 3.79 (1.68, 




compared with White who lived in same region when BrCA-specific mortality was 
examined. In the other three regions of the state (Midlands, Pee Dee and Upstate); there 
were no statistically significant differences in hazard ratio that compared Blacks with 
Whites. Multivariable Cox proportional hazard that adjusted for cancer stage and grade 
showed that the hazard ratio of mortality was 1.53 (1.04,2.26) among Black women who 
lived in urban areas compared with White women who lived in urban areas for all-cause 
mortality. 
Discussion 
The Kaplan Meier model found that there was a statistically significant difference 
between Blacks and Whites in the state of SC overall, however, among the 4 health 
regions, only the Low Country region had statistically significant difference with 
mortality higher among Blacks. This difference is seen as early as 3 years and it 
continues to widen till 12 years. Also, in the Kaplan Meier model, the Low Country 
region had higher BrCA survival than the other three regions, but it also demonstrated the 
widest racial disparity. In Cox Proportional multivariable model, we also showed that 
hazard ratio of mortality was 3.45(1.64,7.25) among Black women who lived in Low 
Country region of the state compared with White women who lived in Low Country 
region of the state when all-cause mortality was examined; and 3.79 (1.68, 8.58) was seen 
among Black women who lived in Low Country region of the state compared with White 
who lived in same region when BrCA-specific mortality was examined. Multivariable 
Cox proportional hazard that adjusted for cancer stage and grade showed that the hazard 
ratio of mortality was 1.53(1.04,2.26) among Black women who lived in urban areas 




The crude hazard ratio of mortality among Blacks compared with Whites was 
1.42 (1.03, 1.95) for overall survival and 1.49 (1.04, 2.14) for BrCA specific survival 
which represents 40% excess risk for overall survival and 50% excess risk for BrCA 
specific survival. However, this finding was no longer significant on multivariable model 
which makes our finding different from previous similar studies in SC that found that 
there is a 60% higher risk of Black women dying from BrCA compared to White women.  
These previous studies showed that although the Black-White disparity in BrCA 
mortality is seen both at the national level and in SC specifically, the disparity is of a 
higher magnitude in SC (5, 30, 40, 41, 156); mortality among White BrCA patients is 7% 
lower in SC compared to the national average and is 29% higher among Blacks in SC 
(30, 40, 41). One of the possible reasons for these differences is because some of the 
studies that assessed the mortality differences in SC utilized age adjusted mortality while 
we utilized the Cox Proportional hazard model with adjustments. For example, a previous 
study that found that a paradoxical relationship of a lower incidence of breast cancer but 
higher death rates among Blacks considered the age-adjusted rate. (156) Our study 
therefore underscores the additional importance of going a step further after utilizing age-
adjusted data to also modelling using statistical means to assess the relationship between 
mortality and race among BrCA patients. 
We found from the Kaplan Meier model that the 5-year, and 12-year survival was 
higher among Whites in the state of SC overall but when this was stratified by region, 
only the Low Country region demonstrated a wide disparity while there was no 
significant difference between Blacks and Whites in the other three regions. This finding 




showed that Blacks in the Low Country region had mortality hazard ratio of 3.45 (1.64, 
7.25) after adjusting for cancer stage, cancer grade and age. This shows that the racial 
disparities seen in BrCA mortality seen in SC is being driven mainly by the disparity seen 
in Low Country region of the state. What is interesting though, is that using the Kaplan 
Meier model, the Low Country had the highest 12-year survival for both all-cause and 
BrCA specific mortality (91.3% and 89.3% respectively). It therefore appears that overall 
(when Blacks and Whites are combined), Low Country has the best mortality outcome 
related to the other three regions but when Black-White disparity is considered, the Low 
Country has the highest racial disparity.    
This finding may be helpful to help inform policy direction in the SC’s state BCN 
program which is an early detection program for breast and cervical cancer (41, 141). 
Women that are eligible for this program are those that are aged 47-64 years, residents of 
SC, underserved/underinsured or do not have insurance and are of low income (less than 
200% of the Federal poverty level). This program provides free breast and cervical cancer 
screening and started because SC has one of the highest rates of uninsured women the 
United States (40, 41, 141). Recruitment into the BCN program is usually through active 
search by federally qualified health centers, the South Atlantic Division, media outlets 
and through outreaches carried out by the American Cancer Society. (41, 141). Our 
finding may help the administrators of the BCN program to plan and focus efforts to 
reduce racial disparities to certain regions of the state or implement special programs for 
those regions. 
Obesity rate may be one of the factors affecting the racial disparities in the Low 




obesity could be the driver of cancer racial disparity. (157) Obesity and comorbid 
illnesses affect Blacks in SC at a rate that is above the national average. (157, 158) In 
2018 report, SC has the 10th highest adult obesity rate in the US, this is up from being the 
13th highest in 2016. Comparing these figures to that of 2000 and 1999 (21.1% and 12% 
respectively), the weight gain problem appears to be persistently on the rise in SC. (157, 
158) A previous study as shown that severe obesity and high waist-to-hip ratio among  
Blacks have also been found to contribute to racial differences in stage at BrCA 
diagnosis, as Blacks had a higher likelihood of severe obesity and being in the highest 
tertile of waist-to-hip ratio (64). SC diabetes and hypertension rate are currently 5th 
highest and 8th highest (13.4% and 38.1% respectively) in the US and physical activity 
ranking 17%. When the obesity rate in SC is broken down by Black-White race, it is 
42.1% (ranking 9th) in Blacks while it is 29.6% (ranking 25th) in Whites. Specifically in 
Charleston, the largest city in the Low Country, the overweight or obese rate is 73.1% 
among Blacks and 63.4% among Whites. (159) When the obesity rate by county was 
ranked, 56% (five out of nine) of counties that had the highest obesity rate in SC (obesity 
rate >40%) were in Low Country region [Allendale, Bamberg, Colleton, Hampton and 
Orangeburg]. (158) 
The regional sub-population of the Gullahs may also be one of the factors 
affecting the racial disparities in the Low Country region of SC. The Gullahs are a unique 
Black sub-population that live and reside in the farming and the fishing communities 
along SC’s coastal areas. (157) The Gullah community are geographically isolated and 
previous studies have shown that they experienced limited access to health care and are at 




Gullah’s limited access to care (though for diabetes mellitus) may also have affected their 
receipt of care for BrCA as shown by other reports that Blacks also have various barriers 
to accessing care. Blacks have been shown to consistently receive lower-than-
recommended BrCA care when compared with their White counterparts (21, 25, 43, 61, 
73, 78). This includes lower-than-recommended rates of radiation after surgical treatment 
for BrCA (25, 43, 61, 78). Blacks have also been shown to be 30-40% more likely to 
receive BrCA treatments that are not in line with guidelines across all BrCA subtypes 
(79). Previous studies have also shown that there is a tendency among Blacks to not 
receive preventative services such as early screening mammograms (77). 
Socioeconomic status (SES) has been identified as one of the main drivers of 
racial disparities in BrCA mortality, as women in low socioeconomic levels tend to 
present with more advanced-stage BrCA, which usually has poorer prognosis (71, 80). 
Specifically, in Charleston, the median income in 2015 for a white family in Charleston–
North Charleston was more than double for black families, $64,553 compared to $29,799. 
That means more than 15,000 black families in Charleston and North Charleston were 
living on the edge of the poverty guideline—$24,250. Charleston County has is of the 
worst counties in the United States in helping poor children up the income ladder. It ranks 
242nd out of 2,478 counties, better than only about 10% of counties nationwide. (159) 
Generally, the five-year survival rate is worse among population subgroups with lower 
SES, which are usually comprised of a large proportion of Blacks (71, 81). Whereas 
about 12% of Whites live below the poverty level, this proportion is 26% among Blacks 
(71, 82). Additionally, when median income by county was ranked, 33 % (five out of 15) 




35,558) were in Low Country region [Allendale, Bamberg, Colleton, Hampton and 
Orangeburg]. (158) These five counties were the same counties with the higher obesity 
rate. (158) 
This study added to existing body of literature on racial disparities on BrCA-
specific survival (BSS), (56) and overall survival (OS) (57, 58). To our knowledge, this is 
the first cancer disparity study in SC that has conducted a regional analysis thereby 
showing that the Low Country region appears to be the driver of the racial disparities 
seen in BrCA patients in SC. One weakness of this study is that we did not assess the 
Hispanic population because the BrCA patients had very low sub-population in SC. 
Additionally, our study was limited in the number of other biological, patient-, physician-
, and healthcare-system-related factors that could have been assessed to further study our 
observations especially in the Low Country region. 
In conclusion, mortality was higher among Blacks who lived in the Low Country 
region of the state and among Blacks who lived in urban areas. Although the Low 
Country region had the highest 12-year survival among a combination of Whites and 
Black population, relative to other three health regions, it demonstrated the highest 
Black-White racial disparity relative to the other three regions. Despite the awareness and 
funding dedicated to closing the racial gap in cancer therapy, it is discouraging to note 
that racial disparities persist in BrCA mortality (60, 61). Navigation programs and other 
available programs aimed at reducing racial disparities may benefit from these finding by 
committing more resources that are culturally acceptable to the Low Country region of 
SC. Considering that Low Country seemed to have the best mortality outcome (when 




may benefit from specific community-oriented interventions similar to the community 
COMPASS project (157) that has the potential to close this gap. To reduce racial 
disparity gap in survival in SC, Black breast cancer patients that live in Low Country 
region and those that live in urban areas may benefit from more intense navigation efforts 
directed at early detection and linkage to receipt of breast cancer treatments. Future 
studies are also required to identify the potential, biological, patient-, physician-, and 
healthcare-system-related factors underlying our observations and optimize cancer care 
among Blacks in SC particularly in the Low Country region. Additionally, the state of SC 
will benefit from future studies to assess the regional disparities in other common cancers 
to identify if this trend seen in the Low Country specific to BrCA or other cancers in 

















Table 5.1 Summary of patients’ characteristics by race 
  N (%) N (%) N (%)  
















386(17.91) 256(16.44) 130(21.74) <0.01 
 45-54 
years old 
924(42.88) 649(41.68) 275(45.99)  
 55-64 
years old 
845(39.21) 652(41.88) 193(32.27)  
Marital status Not 
married 
751(34.85) 436(29.95) 315(57.17) <0.01 
 Married 1256(58.28) 1020(70.05) 236(42.83)  
Rural/Urban 
status 
Urban 1634(75.82) 1232(79.13) 402(67.22) <0.01 
 Rural 521(24.18) 325(20.87) 196(32.78)  
Year of 
diagnosis 
2002-2004 611(28.35) 452(29.03) 159(26.59) 0.02 
 2005-2007 693(32.16) 518(33.27) 175(29.26)  





Positive 926(42.97) 709(81.03) 217(68.89) <0.01 
 Negative 264(12.25) 166(18.97) 98(31.11)  
Stage at 
Diagnosis 




 Local 1013(47.01) 741(47.93) 272(45.95)  
 Regional 657(30.49) 470(30.40) 187(31.59)  
 Distant 46(2.13) 36(2.33) 10(1.69)  
Cancer grade I 392(18.19) 300(21.29) 92(16.76) <0.01 
 II 785(36.43) 608(43.15) 177(32.24)  
 III 749(34.76) 479(34.00) 270(49.18)  
 IV 32(1.48) 22(1.56) 10(1.82)  
Best Chance 
Network 
Yes 119(5.52) 60(3.85) 59(9.87) <0.01 

























Figure 5.1: Kaplan Meier curves for the association between race and 12-year 

















Figure 5.2 Kaplan Meier curves for the association between race and 12-year All-



















Table 5.2: 5-year and 12-year survival by region and by race in South Carolina 
  BrCA-specific survival Overall survival 
  5YST (%) 12YST 
(%) 




Overall 95.6 89.3 94.8 85.8 
 Black 93.3 85.5 92.8 81.2 
 White 96.5 90.1 95.7 87.3 
 p-value  0.03  0.03 
Midlands 
region 
Overall 95.6 89.3 94.8 85.3 
 Black 95.0 90.0 94.3 86.6 
 White 95.8 89.0 94.9 84.9 




Overall 95.5 91.3 95.0 89.3 
 Black 90.3 81.9 89.7 78.8 
 White 98.0 95.6 97.7 94.3 
 p-value  <0.01  <0.01 
Pee Dee Overall 95.2 82.9 93.7 78.5 
 Black 94.7 80.1 95.0 75.7 
 White 95.5 87.4 93.4 82.7 
 p-value  0.67  0.76 
Upstate Overall 96.1 90.7 95.8 87.5 
 Black 92.1 92.1 92.1 84.1 
 White 96.7 90.7 96.1 88.1 






Table 5.3: Table HR and 95% CI for the associations between predictors and all-
cause and BrCA specific mortality by race in SC state overall 
Character
istic 
Race Death Adjusted HR** 




Overall  No (%) HR (CI) HR (CI) 
 White 112(7.19) 1.00 1.00 
 Black 57(9.53) 1.28(0.92,1.77)a 1.30(0.90,1.88)a 
Married     
Yes White 70(6.86) 1.00 1.00 
 Black 11(4.66) 0.78(0.41,1.47)b 0.71(0.35,1.46)a 
No White 36(8.26) 1.00 1.00 
 Black 41(13.02) 1.53(0.97,2.42a 1.78(1.06,3.01)e 
Urban     
Yes White 80(6.49) 1.00 1.00 
 Black 39(9.70) 1.53(1.04,2.26)a 1.53(0.98,2.41)a 
No White 32(9.85) 1.00 1.00 
 Black 18(9.18) 0.91(0.51,1.62)c 0.81(0.42,1.55)c 
Region     
Low 
Country 
White 11(3.77) 1.00 1.00 
 Black 19(12.70) 3.45(1.64,7.25)c 3.79(1.68,8.58) 
Midlands White 44(9.02) 1.00 1.00 
 Black 12(6.59) 0.68(0.35,1.31)a 0.72(0.35,1.51)a 
Pee Dee White 24(9.23) 1.00 1.00 
 Black 18(10.29) 0.99(0.53,1.86)d 0.94(0.44,1.98)f 
Upstate White 33(6.38) 1.00 1.00 
 Black 8(8.99) 1.43(0.66,3.10)c 1.32(0.54,3.21) 
BCN     
Yes White 2(3.33) 1.00 1.00 
 Black 11(18.64) 1.43(0.66,3.10)e 1.32(0.54,3.21)e 
No White 110(7.35) 1.00 1.00 
 Black 46(8.53) 1.22(0.86,1.72)a 1.14(0.77,1.70)a 
Insurance     
1 White 65(5.07) 1.00 1.00 
 Black 21(5.87) 1.09(0.66,1.80)a 1.06(0.61,1.85)a 
2* White 47(17.09) 1.00 1.00 
 Black 36(15.00) 0.89(0.57,1.40)g 0.83(0.49,1.39)a 
aAdjusted for stage and grade. bAdjusted for stage and age. 
cAdjusted for stage. dAdjusted for stage, grade and age. 
eCrude HR reported because no additional variable met entry into the model for 
adjustment. 
fAdjusted for age and grade 





GEOSPATIAL ASSESSMENT OF RACIAL BREAST CANCER 
DISPARITY IN MORTALITY-TO-INCIDENCE RATIO AND 
SURVIVAL ANALYSES CORRELATION IN SOUTH CAROLINA.
 
Introduction 
The epidemiologic use of the mortality-to-incidence ratio (MIR) in cancer 
research is gaining significance and is increasingly used (5, 10-14, 38) as a unique way to 
quantify cancer disparities based on race (5, 10). The MIR is an important indicator that 
offers additional information beyond what is represented through the individual incidence 
and mortality rate measures. (5) The MIR also serves as a population-based 
approximation of fatality (1/survival) given incidence by stabilizing the incidence and 
mortality differences across cancer sites and racial groups (5, 10). Recommendations 
have been made for cancer surveillance programs to use MIRs to monitor disparities 
across racial/ethnic groups and geographic regions (5, 10-14, 38) as a proxy for survival, 
but there is paucity of studies that assessed the effectiveness of MIR as a proxy for 
survival among BrCA patients, especially in South Carolina where there is marked 




Previous studies have utilized the MIR as a surveillance tool and shown that SC 
exhibits more extreme racial differences in cancer incidence, mortality and MIR than 
other states or the nation. (30-38) Additionally, examining the MIR helped to highlight 
health regions where this disparity is highest. (38) A major drawback of the MIR, 
however, is that there is no method to account for censoring and loss to follow up. 
Additionally, the MIR most likely counts the mortality from previous years while using 
incidence from the current year hence it is not a classic case fatality proportion.  It is also 
not possible to adjust for covariates such as treatment, comorbidities or individual 
socioeconomic status in MIR analysis. Another weakness is that the relationship between 
the numerator (mortality) and the denominator (incidence) may not be direct because 
persons diagnosed with BrCa may not die of BrCa, and persons who die after the 
diagnosis of BrCa will survive for varying lengths of time, which the MIR cannot 
account for. 
The limitations of the MIR described above make it difficult to compare results of 
MIR studies directly with those of survival studies. Survival studies are more complex, 
time-consuming and expensive and require more skills to carry out. Additionally, data 
needed to conduct survival analyses is not publicly available and date of diagnosis and 
death are protected data elements which most cancer registries will not release. Using 
MIR is less time-consuming, less expensive and requires fewer skills to carry out. (5) The 
potential utility of the MIR in cancer surveillance programs for monitoring disparities 
across racial/ethnic groups and geographic regions is substantial, as shown by previous 
studies. (5, 10, 12, 14, 38) It is therefore important to see how the MIR compares with 




purpose of surveillance. To our knowledge, this is the first study that seeks to directly 
compute MIR by health regions and compare this ranking with a ranking produced by 
median survival time to further substantiate the usefulness of the MIR in resource-poor 
settings and in quick decision making to identify areas that need urgent interventions. 
This study added further to the usefulness of MIR that was found from a 
sensitivity analysis described previously by Sunkara et al. (152) that examined the effect 
of moving across different “denominator years” to vary with the alignment of the average 
incidence-to-mortality time interval. The sensitivity analysis used all combinations of sex 
and race for cancers involving all anatomic sites. It was shown that the lines describing 
the MIR remained parallel, with the rates generally remaining stable over time across 
eight different 5-year periods beginning in 1996. This analysis was performed using 
incidence data from the SC Central Cancer Registry (SCCCR) (152).  
The aim of this work is to assess the validity of MIR as a proxy for survival and 
geospatially investigate racial disparity among BrCA patients. This was achieved by 
comparing the MIR methodology with survival methodology in assessing racial BrCA 
disparities across the four health regions in SC. We hypothesize that the MIR will be a 
valid analyses compared with survival analyses by region. 
Methods  
Data for survival analyses 
Data for survival analyses is from a retrospective cohort study (2002 to 2010) that 
included data on all BrCA patients derived from linked files from the SCCCR and Office 




for the South Carolina Public Employee Benefits plan and Medicaid). The study was 
exempt from IRB review by the University of South Carolina IRB because it was a 
deidentified data. All newly diagnosed cases of cancers are collected by SCCCR, which 
is a population-based system in SC. Data in the SCCCR include information on 
demographics, diagnosis date, cancer location and histology, treatment and overall 
survival. (38)  
The data was linked with data from SC Revenue and Fiscal Affairs Office (RFA) 
which is an independent agency that houses administrative claims data from both SC 
State Employee Health Plan and SC Medicaid plan members. The RFA developed a 
series of algorithms using various combinations of personal identifiers to create its own 
unique identifier, enabling statistical staff to “link across” multiple providers and settings.  
Hence, it allows for linkages while protecting the confidentiality of the client. The SC 
Revenue and Fiscal Affairs Office and SC Central Cancer Registry frequently work 
together to complete data linkage requests for researchers in SC. All BrCA cases between 
the time period of 2002 to 2010 who met eligibility criteria (that could be ascertained 
from their files) were given to RFA. Then RFA matched to determine which cases linked 
and further met our eligibility criteria (that required claims data to ascertain).  This 
resulted in the 2155 cases.  This resulting combined dataset was used to conduct all 
analyses. 
This cohort was linked to the same patients in the SC State Employee Health Plan 
and Medicaid datasets. The resulting combined dataset will be used to conduct all 
analyses. Linkages were made with 3 personal identifiers: name, date of birth and social 




with SCCCR.  Because of data security issues, only the final de-identified dataset was 
released to study personnel and investigators for analysis. The key to the de-identified 
dataset was retained by RFA in the event that further data clarifications are needed from 
the primary record. Once the de-identified data were received, the study data manager 
performed routine outlier and logic checks. Any improbable values were verified with 
RFA or SCCCR and rectified where possible.  
To create an analytic dataset, we utilized datasets from the RFA (Medicaid and 
State Health Plan), BCN and SCCCR to create an extensive look at breast cancer 
treatment in South Carolina for Black and White women. Data acquisitions were linked 
through the aforementioned departments by the RFA, and only a study participant 
number was assigned to each person for analysis by investigators. Because the final 
dataset was completely de-identified, the investigators have no linkages to the original 
identifiable patient contact information and will be referred to via a study participant 
number only.  
Data for the MIR 
Data for the MIR were obtained from SC Central Cancer Registry (SCCCR) 
online query system which is in the SC Department of Health and Environmental Control 
(DHEC) Office of Public Health Statistics and Information Services. Aggregate data for 
the age-adjusted mortality and incidence rates were obtained from the SC DHEC. Data on 
breast cancer was used in computing the incidence and mortality rates for BrCA, All 
incident BrCA cases are required by law to be reported to SCCCR, a resource established 
with funding from an award from the National Program of Cancer Registries (NPCR) in 




collected by SCCCR on all cancers, both in-situ and invasive, from hospitals, pathology 
laboratories, freestanding treatment centers and physician offices. The only exceptions 
are in situ forms of cervical cancer and invasive forms of basal and squamous cell skin 
cancers of non-genital sites.  
The SCCCR from which we will derive the data for this analysis has a history of 
receiving the highest/gold rating for data completeness (>94%), timeliness and data 
quality from the North American Association of Central Cancer Registries and NPCR. 
SCCCR is a member of the CDC National Interstate Data Exchange System (N-IDEAS), 
such that any member state may share resident incident cases with others to ensure the 
completeness of incident cancer data. Additionally, there is geocoding of all cancer cases 
and cancer deaths in the state of SC.  
Variables for survival analyses 
For the Kaplan Meier analyses and Cox Proportional hazard analyses, the main 
predictor variable was race of the BrCA cases, dichotomized as Black or White. We 
utilized vital status, total survival time, and BrCA cause of death (yes/no) for this 
investigation. From cause of death information, we were able to examine both all-
cause/overall mortality, as well as BrCA-specific mortality. For Cox Proportional 
analyses (to compute hazard ratio by region), additional variables that were considered as 
covariates or effect modifiers were age, marital status, county of residence, year of 
diagnosis, hormone receptor status, enrollment in BCN (dichotomized as yes or no), stage 




Variables for MIR 
Comparisons of MIRs across the four DHEC health regions (Upstate, Midlands, 
Low Country and Pee Dee) was carried out. The variables that were utilized to calculate 
the MIR were age-adjusted incidence and age-adjusted mortality. Variables that were 
used to stratify the MIR maps across the four health regions are race of the BrCa cases 
dichotomized as Black or White.   
Analyses 
Survival Analyses 
Kaplan -Meier survival curves were used to explore 5-year survival and 12-year 
survival for BrCA-specific and all-cause survival at the state and regional levels. This 
was also stratified by race at the state and regional levels. Log rank test was used to 
assess the Kaplan-Meier plot with respect to the main exposure (race) within the four 
regions in SC. 
Computing MIR 
This study described BrCA disparities in SC among Blacks and Whites using 
MIRs by race for the four health regions and by 46 counties within SC. We proceeded to 
rank the four health regions by race from the worst to the best using MIRs. MIR were 
computed from Cancer incidence and mortality data which were obtained from the SC 
Community Access Network. In order to compare racial differences in BrCa MIRs in the 
four SC DHEC health regions, seven categories (for county maps) of BrCa MIRs were 
defined. First, the MIR were computed for Whites nationally (93) (i.e., for the US from 




reference. The upper limit for Category 1 was the reference; the upper limit of Category 2 
was 10% higher than the reference; the upper limit of Category 3 was 20% higher than 
the reference; the upper limit of category 4 was 30% higher than the reference; the upper 
limit of category 5 was 40% higher than the reference; the upper limit of category 6 was 
50% higher than the reference and Category 7 consisted of MIRs >50% higher than the 
reference. This method of categorization and analysis was adapted from a previous study 
by Hebert et al. and Babatunde et al. (5, 38) 
Computing MIR for four health regions: 
BrCa MIRs by race (Black vs. White) were computed for years 2002-2010. Years 
2002 to 2010 will be utilized to mirror the years of registry data that were obtained for 
the survival analyses. The age-adjusted incidence and mortality rates will first be 
calculated using incidence and mortality data from SCCCR. MIRs were stratified by race, 
specifically Blacks versus Whites.  
Computing MIR for 46 counties: 
BrCa MIRs by race (Black vs. White) were computed for years 1996-2016. 
Additional years were utilized to compute Black-White differences in MIR. This was not 
utilized for the MIR-Survival comparison because the years were outside the range for 
the survival data. This was utilized to visually inspect the extent of the Black-White 
disparities that exist when mapped in ArcGIS. 
Interpreting the MIR 
As a ratio with the mortality rate as the numerator and the incidence rate as the 




indicate more indolent cancers, whereas those closer to 1 indicate more aggressive 
cancers. The MIR, which has been shown to be highly insensitive to time-discordant 
incidence and mortality (152), does not take into account follow-up time and is not 
equivalent to Cox proportional hazards–type survival analysis, which is a truly 
multivariate technique that accounts for follow-up time. Similarly, the MIR cannot 
account for competing risk.  
Mapping to visually compare MIR and Survival using ArcGIS 10.2 
ArcGIS 10.2 was utilized to map BrCA MIRs by race (46 counties and 4 regions). 
MIR were categorized into seven levels (as described above) using the national MIR for 
BrCA as reference in county map. In order to map BrCA MIRs by race across the four 
health regions in SC, the categorizations were made based on the natural breaks created 
by ArcGIS. In ArcGIS, MIRs were mapped using choropleth maps that utilized graduated 
colors under quantities. The color ramp that were utilized for the maps was a color 
spectrum that consisted of green (the best/lower MIR) to red (the worst/higher MIR). 
Also, in ArcGIS, survival was symbolized using graduated symbols under quantities with 
a blue circle 22. The biggest circle size symbolized worse/lowest survival while the 
smallest circle size symbolized best/highest survival. 
Correlation analyses to compare MIR and Survival using SAS 9.4 
Survival-MIR correlation analyses were computed for all BrCA cases in each 
county/region utilizing SAS software. SAS® Version 9.4 (Cary, NC) was utilized to 




analysis was also computed comparing hazard ratio with MIR. Pearson’s correlation was 
utilized, and statistically significant correlation was determined using a p-value of 0.05. 
Results 
A total of 2155 breast cancer patients (nWhites=1557/72%; nBlacks= 598/28%) were 
reported in the study period. Table 1 shows the MIR by county by race. Graphically, in 
Figure 1, the map showed that Blacks were in the higher MIR categories in almost all 
counties while Whites were in the lower MIR categories in almost all the counties. Table 
2 showed that the largest Black-White difference in all-cause 12-year and 5-year survival 
percentage was seen in Low Country region (15.5% and 8.0% respectively). The largest 
Black-White difference in BrCA specific 12-year and 5-year survival percentage was also 
seen in Low Country region (13.7% and 7.7% respectively). Although the lowest MIR 
overall was seen in the Low Country region when the entire population of Whites and 
Blacks were considered, the highest difference in Black-White MIR was also seen in the 
Low Country region.  
The crude hazard ratio of mortality among Blacks compared with Whites was 
1.42 (1.03, 1.95) for overall survival and 1.49 (1.04, 2.14) for BrCA specific survival (not 
presented in table). Multivariable cox proportional hazard that adjusted for cancer stage 
showed that the hazard ratio of mortality was 3.45 (1.64,7.25) among Black women who 
lived in Low Country region of the state compared with White women who lived in Low 
Country region of the state when all-cause mortality was examined. A similar hazard 
ratio of mortality of 3.79 (1.68, 8.58) was seen among Black women who lived in Low 
Country region of the state compared with White who lived in same region when BrCA-




Dee and Upstate); there were no statistically significant differences in hazard ratio that 
compared Blacks with Whites.  
Table 3 presented the Pearson Correlation coefficients that compared MIR with 5-
year survival, 12-year survival and adjusted hazard ratios for all-cause and BrCA-specific 
survival for all patients and stratified by race.  When MIR for all cases were considered, 
there was statistically significant correlation between MIR for all cases and BrCA 
specific 12-year survival (p: 0.01; r: -0.99); between MIR for all cases and all-cause 12-
year survival (p: <0.01; r: -0.99). The relationship showed that the higher the MIR, the 
lower the survival. Similar pattern was shown with MIR for Whites and survival but there 
was no statistically significant correlation between MIR for Blacks and their survival 
percentage. There was also significant correlation between the difference in White-Black 
BrCA specific 5-year survival and difference in Black-White MIR (p: 0.03; r: 0.97); 
between the Black versus White adjusted multivariable all-cause hazard ratio and 
difference in Black-White MIR (P: 0.05; r: 0.95). 
Figure 2 graphically shows the relationship between survival and MIR for all 
cases while Figure 3 graphically shows same relationship among Whites. Both maps 
showed that there is a strong correlation between MIR and survival. The higher the 
survival percentage (positive and desired), the lower the MIR (positive and desired). 
Since this relationship was not seen among Blacks, this was not mapped. Figure 4 
graphically shows the relationship between the Black-White difference in MIR and 
White-Black difference in BrCA specific 5-year survival (p: 0.03; r: 0.97). This showed 




in Figure 4, all-cause hazard ratio for Blacks versus Whites was highest in the Low 
Country region where the Black-White difference was highest.   
The map showed that Blacks were in the higher MIR and lower survival 
categories while Whites were in the lower MIR and higher survival categories. There 
were multiple statistically significant correlations between MIR and survival overall; 
MIR and survival among Whites; and Black-White difference in MIR versus Black-
White difference in survival (all p-values were <0.05). Low Country region was 
identified as the region with worse Black-White MIR and survival disparity. 
Discussion 
This study found that Blacks were in the higher/worse MIR categories in most of 
the counties while Whites were in the lower/better MIR categories in most of the 
counties. The largest Black-White difference was seen in Low Country region. While the 
lowest/better MIR overall was seen in the Low Country region when the entire 
population of Whites and Blacks were considered, the highest difference in Black-White 
MIR was also seen in the Low Country region. When MIR for the entire population were 
considered, there was statistically significant correlation between MIR and survival (p: 
0.01; r: -0.99); between MIR for all cases and all-cause 12-year survival (p: <0.01; r: -
0.99). The relationship showed that the higher the MIR, the lower the survival. Similar 
pattern was shown with MIR for Whites and survival but there was no statistically 
significant correlation between MIR for Blacks and their survival percentage. 
Additionally, we found that there was also significant correlation between the difference 




0.03; r: 0.97); between the Black versus White adjusted multivariable all-cause hazard 
ratio and difference in Black-White MIR (P: 0.05; r: 0.95). 
Recommendations have been made for cancer surveillance programs to use MIRs 
to monitor disparities across racial/ethnic groups and geographic regions (5, 10-14, 38) as 
a proxy for survival and our study helped to assess the effectiveness of MIR as a proxy 
for survival using cancer-specific survival among BrCA patients, especially in South 
Carolina where there is marked Black-White disparity. (38) Our finding showed that MIR 
mirrors BrCA survival across the health regions. Asadzadeh et al computed the validity 
of the MIR as a proxy for site-specific cancer survival in 2010 in which relative survival 
data was utilized. (162)  
We have shown that despite the known drawbacks of MIR such as not accounting 
for censoring and loss to follow up, counting the mortality from previous years while 
using incidence from the current year, inability to account for covariates and competing 
risks; the MIR is still a fair reflection of survival and racial disparities. The MIR may 
therefore be utilized as a proxy for survival studies which are a more complex, time-
consuming and expensive analyses that require more skills to carry out. Using MIR is 
less time-consuming, less expensive and requires fewer skills to carry out. (5) Therefore, 
the potential utility of the MIR in cancer surveillance programs for monitoring disparities 
across racial/ethnic groups and geographic regions is substantial, as shown by previous 
studies. (5, 10, 12, 14, 38) and our current study.  
Our study also found that the Black-White MIR difference is highest in the Low 




This also agrees with the use of the MIR as a surveillance tool in past studies which 
underscores the point that SC exhibits more extreme racial differences in cancer 
incidence, mortality and MIR than other states or the nation. (30-37) Specifically, in a 
previous study in SC, the MIR helped highlight regions where this disparity is highest 
(38). For example, in this past study, the Pee Dee region in SC have the highest MIR 
disparity, where the MIRs of Blacks are 3.1 and 3.0 times higher, respectively, than those 
of Whites. Also, in our current study, the MIR for Blacks was highest in the Pee Dee 
region (0.217) although the Black-White disparity was highest in the Low Country 
region. 
The Pee Dee region is known for its lower socioeconomic status, rurality and 
being medically underserved (5). Additionally, in four of the 12 counties in the Pee Dee 
regions (Dillon, Lee, Marlboro and Williamsburg), over 40% of adults report a BMI of 
30 or more (153). Similarly,  the percentage of adults aged 20 and over reporting no 
leisure-time physical activity was greater than 30% in seven counties (Chesterfield, 
Darlington, Dillon, Lee, Marion, Marlboro and Sumter) out the 12 counties in the Pee 
Dee region (153). The usefulness of the MIR in racial disparity was also buttressed by the 
study by Wagner et al. that described racial cancer disparities and their potential 
geographical determinants by calculating, comparing and mapping MIRs throughout the 
state of Georgia (GA, United States). This study found that Blacks in GA had more fatal 
cancers than Whites for all cancer sites evaluated (10). Additionally, examining the MIR 
helped to highlight health regions where this disparity is highest. (38)  
Our study also showed the importance of the assessment of racial disparity in 




disparity is highest in the Low Country region. This finding that highlighted the region 
with the highest disparity in SC may be useful to help inform policy direction in the SC’s 
state BCN program which is an early detection program for breast and cervical cancer 
(41, 141).  
Obesity rate may be one of the factors affecting the racial disparities in the Low 
Country region of SC. In SC, it has been hypothesized that comorbid illnesses and 
obesity could be the driver of cancer racial disparity. (157) Obesity and comorbid 
illnesses affect Blacks in SC at a rate that is above the national average. (157, 158) In 
2018 report, SC has the 10th highest adult obesity rate in the US, this is up from being the 
13th highest in 2016. Comparing these figures to that of 2000 and 1999 (21.1% and 12% 
respectively), the weight gain problem appears to be persistently on the rise in SC. (157, 
158) The regional sub-population of the Gullahs may also be one of the factors affecting 
the racial disparities in the Low Country region of SC. The Gullahs are a unique Black 
sub-population known as the that live and reside in the farming and the fishing 
communities along SC’s coastal areas. (157)  
The Gullah community are geographically isolated and previous studies has 
shown that they experienced limited access to health care and that they are at a higher 
risk of cardiometabolic risk factors for diabetes mellitus. (160, 161) Socioeconomic 
status (SES) has been identified as one of the main drivers of racial disparities in BrCA 
mortality, as women in low socioeconomic levels tend to present with more advanced-
stage BrCA, which usually has poorer prognosis (71, 80). Specifically, in Charleston, the 
median income in 2015 for a white family in Charleston–North Charleston was more than 




A previous report shows that predictors that are environmental in nature affect 
health and disparity, (59) but the influence of geographical factors has not been well 
explored among younger women. This is particularly important because young Black 
women (less than 65 years old) present with relatively more fatal BrCA, leading to higher 
mortality among this group. (30, 40) Most studies on the MIR have been on international 
comparisons of the MIR based on cancer management outcomes, health care systems 
ranking, national healthcare disparities, across several countries. (162-169) We have 
added to the literature that MIR can also be applied locally for the purpose of surveillance 
and assessment of racial disparities.  
To our knowledge, this is the first study that seeks to directly compute MIR by 
health regions and compare this ranking with a ranking produced by five-year and 12-
year survival time to further substantiate the usefulness of the MIR in resource-poor 
settings and in quick decision making to identify areas that need urgent interventions. The 
is also the first time that the MIR will be utilized to assess BrCa disparities in addition to 
the direct sensitivity analyses comparing MIR with survival analyses both on the state 
and regional level. Identifying predictors of racial differences in survival by regions is 
also unique as findings has the potential to help guide more result-oriented navigation 
efforts. Overall, the study population (SC) in this study is unique because of the high 
proportion of SC residents that live in rural areas and the high racial disparity found in 
SC in other studies. (38, 170) One weakness however, of this study is that we did not 
assess the Hispanic population because the BrCA patients had very low representation in 
SC. Another weakness is that the data that we utilized for survival analyses was limited to 




contained all BrCA patients (this was necessary to get an age-adjusted mortality and 
incidence). Because we got the incidence and mortality data from the South Carolina 
Community Assessment Network/Department of Health and Environmental Control 
website, there was no way to remove the 65+ from the data and still get an age-adjusted 
rate. 
This study finds that the health region ranking utilizing the MIR was highly 
correlated with survival time in the overall population and among White population. It 
may therefore be preferable to use the cheaper, faster and less time-consuming MIR, 
which also requires fewer skills, to identify geographic disparities and rank health regions 
to identify areas that require urgent attention/interventions. Additionally, the MIR is 
cheap and easy to compute from existing relatively complete data. The MIR can be used 
as a surrogate measure for a more expensive and time-consuming survival studies (38). 
Additional studies with larger sample size may help to understand the relationship 
between MIR and survival among Black population. Cancer surveillance programs may 
use the MIR to monitor disparities across racial/ethnic groups and geographic regions 
going forward. MIRs have the potential to serve as an indicator of the long-term success 














County MIR Blacks MIR Whites 
Abbeville 0.19 0.12 Greenwood 0.20 0.16 
Aiken 0.23 0.16 Hampton 0.25 0.17 
Allendale 0.29 0.19 Horry 0.26 0.15 
Anderson 0.17 0.14 Jasper 0.28 0.16 
Bamberg 0.24 0.16 Kershaw 0.19 0.15 
Barnwell 0.26 0.14 Lancaster 0.24 0.13 
Beaufort 0.20 0.12 Laurens 0.21 0.15 
Berkeley 0.15 0.13 Lee 0.30 0.16 
Calhoun 0.18 0.19 Lexington 0.19 0.14 
Charleston 0.20 0.11 McCormick  0.12 
Cherokee 0.26 0.18 Marion 0.24 0.23 
Chester 0.27 0.18 Marlboro 0.24 0.15 
Chesterfield 0.19 0.18 Newberry 0.21 0.14 
Clarendon 0.19 0.18 Oconee 0.26 0.15 
Colleton 0.18 0.15 Orangeburg 0.24 0.14 
Darlington 0.26 0.17 Pickens 0.22 0.12 
Dillon 0.24 0.19 Richland 0.20 0.13 
Dorchester 0.20 0.12 Saluda 0.29 0.19 
Edgefield 0.26 0.16 Spartanburg 0.23 0.15 
Fairfield 0.20 0.15 Sumter 0.19 0.16 
Florence 0.26 0.15 Union 0.23 0.18 
Georgetown 0.20 0.14 Williamsbur
g 
0.27 0.18 









Figure 6.1: Racial disparities in mortality-to-incidence ration of Breast Cancer for 




















Table 6.2 Breast Cancer: aSurvival Proportion and Mortality to Incidence Ratio 
(MIR) (2002-2010) in South Carolina by Race and Health Region 
 All White Blacks White
-Black 




































eLC 89.3 94.3 78.8 15.5 95.0 97.7 89.7 8.0 
MD 85.3 84.9 90.0 -5.1 94.8 94.9 94.3 0.6 
PD 78.5 82.7 75.7 7.0 93.7 93.4 95.0 -1.6 
UP 87.5 88.1 84.1 4.0 95.8 96.1 92.1 4.0 
         
 All White Blacks White
-Black 

































LC 91.3 95.6 81.9 13.7 95.5 98.0 90.3 7.7 
MD 89.3 89.0 90.0 -1.0 95.6 95.8 95 0.8 
PD 82.9 87.4 80.1 7.3 95.2 95.5 94.7 0.8 
UP 90.7 90.7 92.1 -1.4 96.1 96.1 92.1 4 
         










MIR MIR MIR MIR Black White Black White 
LC 0.155 0.133 0.207 0.074 c3.45 1.00 g3.79 1.00 
MD 0.163 0.145 0.208 0.063 d0.68 1.00 a0.72 1.00 
PD 0.177 0.151 0.217 0.066 e0.99 1.00 f0.94 1.00 
UP 0.159 0.145 0.214 0.069 c1.43 1.00 g1.32 1.00 
a5YS: 5-year survival; 12YS: 12-year survival; BrCA: Breast Cancer.  
bLC: LowCountry region; MD: Midland region; PD: PeeDee region; UP: Upstate region. 
cAdjusted for stage 
dAdjusted for stage and grade. 
eAdjusted for stage, grade and age 
fAdjusted for age and grade 








Table 6.3: Correlation between aSurvival Proportion and Mortality to Incidence 
Ratio (MIR) (2002-2010) in South Carolina among Breast Cancer Patients by race 
and region. 
Survival Variable MIR Variable p-value Pearson 
Correlation 
Coefficient 
Survival by MIR for all patients    
bBrCA Specific 12 YS (All patients) MIR (All 
patients) 
0.01 -0.99 
All Cause 12 YS (All patients) MIR (All 
patients) 
<0.01 -0.99 
BrCA Specific 5YS (All patients) MIR (All 
patients) 
0.37 -0.63 
All Cause 5YS (All patients) MIR (All 
patients) 
0.15 -0.85 
    
Black survival by Black MIR    
Black BrCA Specific 12 YS Black MIR 0.85 0.15 
Black All Cause 12 YS Black MIR 0.52 -0.48 
Black BrCA Specific 5 YS Black MIR 0.62 0.38 
Black All Cause 5 YS Black MIR 0.45 0.55 
    
White survival by White MIR    
White BrCA Specific 12 YS White MIR 0.02 -0.976 
White All Cause 12 YS White MIR 0.03 -0.97 
White BrCA Specific 5 YS White MIR 0.02 -0.97 
White All Cause 5 YS White MIR 0.06 -0.94 
    
Survival disparity by MIR 
disparity 
   
White-Black BrCA Specific 12 YS Black-White MIR 0.30 0.70 
White-Black All Cause 12 YS Black-White MIR 0.09 0.91 
White-Black BrCA Specific 5YS Black-White MIR 0.03 0.97 
White-Black All Cause 5 YS Black-White MIR 0.11 0.88 
    
Hazard Ratio by MIR disparity    
All Cause Hazard Ratio Black versus 
White 
Black-White MIR 0.05 0.95 
BrCA Specific Hazard Ratio Black 
versus White 
Black-White MIR 0.07 0.93 
a5YS: 5-year survival; 12YS: 12-year survival;  






Figure 6.2: Mortality-to-incidence ration of Breast Cancer for South Carolina 
















Figure 6.3: Mortality-to-incidence ratio of White Breast Cancer patients in South 
















Figure 6.4: Racial disparity in Mortality-to-incidence of Breast Cancer in South 















The aims of this study were: 
1. To assess racial disparities in BrCA treatment time in South Carolina (SC) by 
comparing diagnosis-to-treatment times for the various forms of treatment in 
Blacks and Whites with BrCA and to assess related effect modifiers. We 
hypothesize that the diagnosis-to-treatment wait time is higher among Blacks 
compared to Whites for all BrCA treatment types in SC.  
2. To analyze the breast cancer-specific and overall survival in SC, as well as by 
four health regions and to assess the factors (confounders and effect modifiers) 
affecting survival among Black and Whites in SC overall. We hypothesize that 
treatment and mortality outcomes will be worse for Blacks who live in Pee Dee, 
which are characterized by lower socioeconomic status, and will be better in 
Midlands and Low Country because of the major hospital systems available in 
these regions. 
3. To assess the effectiveness of MIR as a proxy for survival and geospatially 
investigate racial disparity among BrCA patients. This was achieved by 




4. BrCA disparities across the four health regions in SC. We hypothesize that the 
findings from MIR by regions will be similar to the survival analyses by regions. 
Main Findings 
This study demonstrated that there was a longer diagnosis-to-treatment time for 
all treatment modalities for Blacks when compared with Whites. Late receipt of AHT was 
higher among blacks that were unmarried, received late surgery, and not a participant of 
the BCN. We also found that late receipt of surgery was higher among blacks that were 
unmarried, lived in urban areas and those who lived less than 10 miles to their health care 
provider. The only sub-group where whites had a later receipt of treatment was for post-
surgery radiation among hormone receptor negative BrCA patients.  
In addition to showing that there were longer diagnosis-to-treatment time in 
which has been demonstrated from previous studies, (18, 22, 26, 74, 128) we were able to 
add the following to the racial disparity discussion: the impact of being unmarried, living 
in urban areas, enrolment in BCN, and distance on late receipt of treatment. This study 
also showed the positive relationship between late receipt of surgery and time to AHT 
demonstrating that those who are late to receive one form of treatment are likely to be 
late at the receipt at other forms of treatment. The use of the findings in this paper has the 
potential to further enhance the understanding of navigation of health care process and 
strengthen navigation efforts aimed at linking women with BrCA to care especially 
among blacks thereby reducing racial disparities. 
The Kaplan Meier model found that there was a statistically significant difference 
between Blacks and Whites in the state of SC overall, however, among the 4 health 




mortality higher among Blacks. This difference is seen as early as 3 years and it 
continues to widen till 12 years. Also, in the Kaplan Meier model, the Low Country 
region had higher BrCA survival than the other three regions, but it also demonstrated the 
widest racial disparity. In Cox Proportional multivariable model, we also showed that 
hazard ratio of mortality was 3.45(1.64,7.25) among Black women who lived in Low 
Country region of the state compared with White women who lived in Low Country 
region of the state when all-cause mortality was examined; and 3.79 (1.68, 8.58) was seen 
among Black women who lived in Low Country region of the state compared with White 
who lived in same region when BrCA-specific mortality was examined. Multivariable 
Cox proportional hazard that adjusted for cancer stage and grade showed that the hazard 
ratio of mortality was 1.53(1.04,2.26) among Black women who lived in urban areas 
compared with White women who lived in urban areas for all-cause mortality. 
We also found that Blacks were in the higher/worse MIR categories in most of the 
counties while Whites were in the lower/better MIR categories in most of the counties. 
The largest Black-White difference was seen in Low Country region. While the 
lowest/better MIR overall was seen in the Low Country region when the entire 
population of Whites and Blacks were considered, the highest difference in Black-White 
MIR was also seen in the Low Country region. When MIR for the entire population were 
considered, there was statistically significant correlation between MIR and survival (p: 
0.01; r: -0.99); between MIR for all cases and all-cause 12-year survival (p: <0.01; r: -
0.99). The relationship showed that the higher the MIR, the lower the survival. Similar 
pattern was shown with MIR for Whites and survival but there was no statistically 




Additionally, we found that there was also significant correlation between the difference 
in White-Black BrCA specific 5-year survival and difference in Black-White MIR (p: 
0.03; r: 0.97); between the Black versus White adjusted multivariable all-cause hazard 
ratio and difference in Black-White MIR (P: 0.05; r: 0.95). 
Conclusions 
In conclusion, late receipt of AHT was higher among blacks that were unmarried, 
received late surgery, and not a participant in BCN. We also found that late receipt of 
surgery was higher among blacks that were unmarried, lived in urban areas and those 
who lived less than 10 miles to their health care provider. There is a longer diagnosis-to-
treatment time in receipt of AHT between blacks and white that are not on BCN but no 
difference between blacks and white on BCN, it therefore suggests that, perhaps the BCN 
is helping to close the racial disparity gap between whites and blacks or those who are on 
BCN have other factors that is driving the racial disparities.  
We also noted found that mortality was higher among Blacks who lived in the 
Low Country region of the state and among Blacks who lived in urban areas. Although 
the Low Country region had the highest 12-year survival among a combination of Whites 
and Black population, relative to other three health regions, it demonstrated the highest 
Black-White racial disparity relative to the other three regions. Despite the awareness and 
funding dedicated to closing the racial gap in cancer therapy, it is discouraging to note 
that racial disparities persist in BrCA mortality (60, 61). Navigation programs and other 
available programs aimed at reducing racial disparities may benefit from these finding by 




SC. Considering that Low Country seemed to have the best mortality outcome (when 
combined data is used) but the worse Black-White disparity, the Low Country region 
may benefit from specific community-oriented interventions similar to the community 
COMPASS project (157) that has the potential to close this gap. 
Our study also showed that the health region ranking utilizing the MIR was highly 
correlated with survival time in the overall population and among White population. It 
may therefore be preferable to use the cheaper, faster and less time-consuming MIR, 
which also requires fewer skills, to identify racial disparities and rank health regions to 
identify areas that require urgent attention/interventions. Additionally, the MIR is cheap 
and easy to compute from existing relatively complete data. The MIR can be used as a 
surrogate measure for a more expensive and time-consuming survival studies (38). 
Recommendations 
The relationship between being on BCN and diagnosis-to-treatment time in 
receipt on AHT will benefit from future studies as it will be important to understand the 
reason for the longer time among those not on BCN. To improve overall timely receipt of 
AHT, efforts need to be directed at Black BrCA patients that are not married, not on BCN 
and received late surgery. To improve overall timely receipt of surgery, efforts need to be 
directed at Black BrCA patients that are not married, lived in urban areas and lived <=10 
miles from health providers. 
To reduce racial disparity gap in survival in SC, Black breast cancer patients that 
live in Low Country region and those that live in urban areas may benefit from more 




cancer treatments. Future studies are also required to identify the potential, biological, 
patient-, physician-, and healthcare-system-related factors underlying our observations 
and optimize cancer care among Blacks in SC particularly in the Low Country region. 
Additionally, the state of SC will benefit from future studies to assess the regional 
disparities in other common cancers to identify if this trend seen in the Low Country 
specific to BrCA or other cancers in order to inform future implementation regional 
appropriate policies that may help to close this gap. 
Additional studies with larger sample size may help to understand the relationship 
between MIR and survival among Black population. Cancer surveillance programs may 
use the MIR to monitor disparities across racial/ethnic groups and geographic regions 
going forward. MIRs have the potential to serve as an indicator of the long-term success 
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